Novartis Institutes for BioMedical Research
ACZ885
Clinical Trial Protocol CACZ885X2206
A multiple -dose, subject -and inv estigator -blinded, 
placebo -controlled, parallel design study  to assess the 
efficac y, safety  and tolerability  of ACZ885 (canakinumab) in 
pediatric and y oung adult patients w ith sickle cell anemia
Document type: Amended Protocol Version
EUDRACT number: 2016 -002101 -19
Version number: v05 (Clean )
Clinical Trial Phase: II
Release date: 22-Mar-2018
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Novartis Confidential Page 2
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Site Operations Manual (SOM)
A Site Operations Manual (SOM) accompanies this protocol, providing the operational details 
for study  conduct. Note: The SOM will not be part of the Clinical Study  Report.
Notification of serious adverse events
Dear Investigator,
You must report a serious adverse event (SAE) (initial or follow -up) to Novartis as 
summarized below.  Refer to Section 9.2 of the protocol for SAE criteria and additional 
requirements.  See also page 2 of the Site Operations Manual for further details on the method 
of reporting a SAE.
Complete SAE report
Submit SAE report to Novartis Chief Medical Office and Patient Safet y (CMO& PS)
within 24 hours after awareness of the SAE
Notify  the Novartis Medical L ead
The fax number(s) and email address(es) are located in the Site Operations Manual. 
Novartis Confidential Page 3
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Table of contents
Site Operations Manual (SOM)........................................................................................... 2
Notification of serious adverse events ................................................................................. 2
Table of contents ................................................................................................................. 3
List of tables ........................................................................................................................ 7
List of figures ...................................................................................................................... 7
List of abbreviations ............................................................................................................ 8
Pharmacokinetic definitions and sy mbols ......................................................................... 11
Glossary  of terms ............................................................................................................... 12
Protocol sy nopsis ............................................................................................................... 23
1Introduction ....................................................................................................................... 27
1.1 Background ............................................................................................................ 27
1.2 Nonclinical data ..................................................................................................... 30
1.2.1 Teratogenicity  and reproductive toxicity  data ....................................... 30
1.3 Clinical data ........................................................................................................... 30
1.3.1 Human safet y and tolerability  data ....................................................... 30
1.3.2
Human pharmacokinetic data................................................................ 32
1.3.3 Human pharmacod ynamic data ............................................................. 32
1.4 Study  purpose ........................................................................................................ 32
2Study  objectives and endpoints ......................................................................................... 33
2.1 Primary  objective(s) ............................................................................................... 33
2.2 Secondary  objective(s) ........................................................................................... 33
2.3 Exploratory  objective(s) ........................................................................................ 34
3Investigational plan ................................ ................................ ................................ ........... 35
3.1 Study  design ........................................................................................................... 35
3.2 Rationale of study  design ....................................................................................... 36
3.3
Rationale for dose/regimen, route of administration and duration of treatment ....38
3.4 Rationale for choice of c omparator ....................................................................... 38
3.5 Rationale for choice of background therap y
.......................................................... 38
3.6
Purpose and timing of interim anal yses/design adaptations .................................. 39
3.7 Risks and benefits .................................................................................................. 39
Commercially Confidential Information
Novartis Confidential Page 4
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
3.7.1 Blood sample volumes .......................................................................... 40
4Population .......................................................................................................................... 41
4.1 Inclusion criteria .................................................................................................... 41
4.2 Exclusion criteria ................................................................................................... 42
5Restrictions for Study  Subjects
......................................................................................... 44
5.1 Contraception requirements ................................................................................... 44
5.2 Prohibited treatment ............................................................................................... 44
5.3 Dietary  restrictions and smoking ........................................................................... 45
5.4
Other restrictions ................................................................................................... 45
6Treatment ........................................................................................................................... 45
6.1 Study  treatment ...................................................................................................... 45
6.1.1 Investigational treatment and control drugs .......................................... 45
6.1.2 Additional study  treatment .................................................................... 45
6.2 Treatment arms ...................................................................................................... 46
6.3
Treatment assignment and randomization............................................................. 46
6.4 Treatment blinding ................................................................................................. 46
6.5 Treating the subject ................................................................................................ 48
6.6 Permitted dose adjustments and interruptions of study  treatment ......................... 48
6.7 Emergency  breaking of assigned treatment code .................................................. 48
6.8 Treatment e xposure and compliance ..................................................................... 49
6.9 Recommended treatment of adverse events .......................................................... 49
6.10
Rescue medication................................................................................................. 49
6.11 Concomitant treatment ........................................................................................... 49
7Study  completion and discontinuation .............................................................................. 50
7.1 Study  completion and post -study  treatment .......................................................... 50
7.2 Discontinuation of study  treatment ........................................................................ 50
7.3 Withdrawal of informed consen t
................................ ................................ ........... 51
7.4 Lost to follow -up ................................................................................................... 51
7.5 Study  Stopping rules .............................................................................................. 52
7.6 Early study termination by the sponsor ................................ ................................ .52
8 Procedures and assessments .............................................................................................. 53
8.1 Assessment schedule ............................................................................................. 53
8.2 Informed consent procedures
................................................................................. 56
8.3
Subject screening................................................................................................... 56
8.4
Subject demographics/other baseline characteristics............................................. 57
8.4.1 Alcohol Test and Drug Screen .............................................................. 57
8.4.2 Tuberculosis status ................................................................................ 57
Novartis Confidential Page 5
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
8.4.3 HIV screen ............................................................................................ 57
8.4.4 Hepatitis screen ..................................................................................... 57
8.5 Efficacy  / Pharmacod ynamics ............................................................................... 57
8.5.1 Clinical Outcome Assessments (COAs) ............................................... 58
8.6 Safet y
..................................................................................................................... 59
8.6.1 Blood pressure ....................................................................................... 59
8.6.2 Body height ........................................................................................... 59
8.6.3 Body temperature .................................................................................. 59
8.6.4 Body weight .......................................................................................... 59
8.6.5 Clinical Chemistry ................................................................................ 59
8.6.6 Hematology ........................................................................................... 59
8.6.7 Immunogenicity .................................................................................... 59
8.6.8 Pulse rate ............................................................................................... 60
8.6.9 Urinal ysis.............................................................................................. 60
8.6.10 Pregnancy  test....................................................................................... 60
8.6.11 Physical examination ............................................................................ 60
8.7 Pharmacokinetics ................................................................................................... 60
8.8 Other assessments .................................................................................................. 61
8.9 Use of residual biological samples ........................................................................ 63
9Safet y monitoring .............................................................................................................. 63
9.1 Adverse events ....................................................................................................... 63
9.2 Serious adverse event reporting ............................................................................. 65
9.2.1 Definition of SAE ................................................................................. 65
9.2.2 SAE reporting
........................................................................................ 66
9.3 Liver safety  monitoring ......................................................................................... 67
9.4 Renal safet y monitoring ......................................................................................... 68
9.5 Reporting Medication errors including misuse/abuse ........................................... 68
9.6 Pregnancy  reporting ............................................................................................... 69
9.7 Early phase safet y monitoring ............................................................................... 69
10Data review and database management ............................................................................. 69
10.1 Site monitoring ...................................................................................................... 69
10.2
Data collection....................................................................................................... 70
Commercially Confidential Information
Novartis Confidential Page 6
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
10.3 Database management and quality  control ................................ ............................ 70
10.4 Data Monitoring Committee .................................................................................. 71
10.5 Adjudication Committee ........................................................................................ 71
11Data analy sis...................................................................................................................... 72
11.1 Analy sis sets .......................................................................................................... 72
11.2
Subject demographics and other baseline characteristics...................................... 72
11.3 Treatments ............................................................................................................. 72
11.4 Analy sis of the primary  variable(s) ....................................................................... 73
11.4.1 Variable(s) ............................................................................................. 73
11.4.2 Statistical model, hy pothesis, and method of analysis .......................... 73
11.4.3 Handling of missing values
/censoring/discontinuations ....................... 74
11.4.4 Sensitivity  anal yses............................................................................... 74
11.4.5 Supportive anal yses............................................................................... 74
11.5 Analy sis of secondary  variable(s) .......................................................................... 74
11.5.1 Efficacy  / Pharmacod ynamics ............................................................... 74
11.5.2 Inflammation and hemoly sis biomarkers at Week 12 ........................... 75
11.5.3
Absence from school/work ................................................................... 75
11.5.4 Incidence of acute blood transfusion
..................................................... 75
11.5.5 Safet y
..................................................................................................... 76
11.5.6 Pharmacokinetics .................................................................................. 76
11.5.7 Pharmacokinetic / pharmacod ynamic interactions ................................ 76
11.5.8 Other assessments ................................................................................. 76
11.6 Analy sis of exploratory  variables
.......................................................................... 77
11.7
Sample size calculation.......................................................................................... 79
11.8 Power for anal ysis of key secondary  variables ...................................................... 80
11.9 Interim anal yses..................................................................................................... 80
12
Ethical considerations........................................................................................................ 81
12.1 Regulatory
 and ethical compliance ........................................................................ 81
12.2 Responsibilities of the investigator and IRB/IEC .................................................. 81
12.3 Publication of study  protocol and results ............................................................... 81
Commercially Confidential Information
Novartis Confidential Page 7
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
13Protocol adherence ................................ ................................ ................................ ............ 81
13.1 Protocol Amendments ........................................................................................... 82
14References ......................................................................................................................... 83
15Appendix 1: L iver Event Definitions and Follow -up Requirements ................................. 87
16Appendix 2: Specific Renal Alert Criteria and Actions .................................................... 89
List of tables
Table 5
-1 Prohibited treatment .............................................................................. 45
Table 6
-1 Blinding levels ...................................................................................... 48
Table 9
-1 Summary  of reporting requirements for medication errors................... 68
Table 11-1 Probability  of meeting decision rules at IA1 ......................................... 80
Table 15
-1 Liver Event Definitions......................................................................... 87
Table 15-2 Actions required for Liver Events ......................................................... 87
Table 15
-3 Exclusion of underly ing liver disease ................................................... 88
Table 16
-1 Specific Renal Alert Criteria and Actions ............................................. 89
Table 16
-2 Follow -up of renal events ...................................................................... 90
List of figures
Figure 3 -
1 Study  design .......................................................................................... 35
Commercially Confidential Information
Novartis Confidential Page 8
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
List of ab breviations
γ-GT gamma -glutam yl transferase
AE adverse event
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
ANC absolute neutrophil count
ANCOVA analysis of covariance
AST aspartate aminotransferase
AUC area under curve
BMI Body Mass Index
BUN blood urea nitrogen
CAPS cyropyrin-associated periodic sy ndromes
CINCA chronic i nfantile neurological , cutaneous, articular sy ndrome
CFR Code of Federal Regulation
CK creatinine kinase
CO 2 carbon dioxide
COAR Clinical Operations, Analy tics & Regions
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CRP C-reactive protein
CTC Common Toxicity  Criteria
CV coefficient of variation
EDC Electronic Data Capture
ELISA enzyme-linked immunosorbent assay
EOS End of study
EU European Union
FCU familial cold urticaria
FCAS Familial Cold Autoinflammatory  Syndrome
FDA Food and Drug Administration
GCP Good Clinical Practice
GLM generalized linear model
Novartis Confidential Page 9
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
h Hour
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HIV human immunodeficiency virus
hs-CRP high-sensitivity  C-reactive protein
Hydroxyurea Hydroxyurea/hy droxy carbamide
i.v. intravenous
IAC Infection Adjudication Committee
ICHInternational Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IL interleukin
IL-18BPa interleukin -18 binding protein
IL-1RA interleukin -1 receptor antagonist
IRB Institutional Review Boa rd
IRT Interactive Response Technology
ITT intention -to-treat
IUD intrauterine device
LDH lactate deh ydrogenase
LFT liver function test
LLN lower limit of normal
LOCF last observation carried forward
MAC Malignancy  Adjudication Committee
MAR missing at random
MCI D Minimally  clinical important difference
MedDRA Medical dictionary  for regulatory  activities
mg milligram(s)
mL milliliter(s)
MMRM Mixed -effect Model for Repeated Measures
MWS Muckle Wells Sy ndrome
NOMID neonatal - o nset m ultisy stem inflammatory  disease
Commercially Confidential Information
Novartis Confidential Page 10
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
PD pharmacod ynamic(s)
PK pharmacokinetic(s)
POC Proof of concept
RBC red blood cell(s)
s.c. subcutaneous
SAE serious adverse event
SCA sickle cell anemia
sCR serum creatinine
SD standard deviation
sJIA systemic juvenile idiopathic arthritis
SOM Site Operations Manual
SUSAR Suspected Unexpected Serious Adverse Reactions
TB tuberculosis
TBL total bilirubin
TCD Transcranial Doppler
TRAPS TNF receptor -associated periodic s yndrome
UK United Kingdom
ULN upper limit of normal
US United States of America
VAS visual analog scale
WBC white blood cell(s)
WHO World Health Organization
Commercially Confidential InformationCommercially Confidential Information
Novartis Confidential Page 11
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Pharmacokinetic definitions and sy mbols
AUCinfThe area under the plasma (or serum or blood) concentration- time curve from 
time zero to infinity  [mass x time / volume]
Cav,ssThe average steady  state plasma (or serum or blood) concentration during 
multiple dosing
CLThe systemic (or total body ) clearance from plasma (or serum or blood) 
following intravenous administration [volume / time]
CL/FThe apparent sy stemic (or total body ) clearance from plasma (or serum or blood) 
following extravascular administration [volume / time]
CLr The renal clearance from plasma (or serum or blood) [volume / time]
CmaxThe observed maximum plasma (or serum or blood) concentration following 
drug administration [mass / volume]
VssThe volume of distribution at steady  state following intravenous admi nistration 
[volume]
Novartis Confidential Page 12
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Glossary  of terms
Assessment A procedure used to generate data required b y the study
Cohort A specific group of subjects fulfilling certain criteria
Control drugAny drug (an active drug or an inactive drug, such as a placebo) which 
is used as a comparator to the investigational drug being tested in the 
trial
DosageDose of the study  treatment given to the subject in a time unit 
(e.g. 100mg once a day , 75 mg twice a day )
EnrollmentPoint/time of subject entry  into the study  at whic h informed consent 
must be obtained (i.e. prior to starting any of the procedures described 
in the protocol)
EpochInterval of time in the planned conduct of a study . An epoch is 
associated with a purpose (e.g. screening, randomization, treatment, 
follow -up), which applies across all arms of a study .
Health y volunteerA person with no known significant health problems who volunteers to 
be a stud y participant 
Investigational drugThe study  drug whose properties are being tested in the study ; this 
definit ion is consistent with US CFR 21 Section 312.3 and Directive 
2001/20/EC and is synony mous with “investigational new drug” or 
“test substance”
Investigational 
treatmentAll investigational drug(s) whose properties are being tested in the 
study  as well as their associated treatment controls. This includes any 
placebos, any active controls, as well as approved drugs used outside 
of their indication/approved dosage or tested in a fixed combination. 
Investigational treatment generall y does not include other treatments 
administered as concomitant background therapy required or allowed 
by the protocol when used within approved indication/dosage.
Medication numberA unique identifier on the label of each study  drug package in studies 
that dispense study  drug usin g an IRT s ystem.
Medication pack 
numberA unique identifier on the label of each drug package in studies that 
dispense study  treatment using an IRT s ystem
Non-investigational 
medicinal Product 
(NIMP)Products which are not the object of investigation (e. g. an y background 
therap y administered to each of the clinical trial subjects, regardless of 
randomization group, rescue medication, active drug run -ins etc.)
PartA single component of a study  which contains different objectives or 
populations within that single study . Common parts within a study  are: 
a single dose part and a multiple dose part, or a part in patients with 
established disease and in those with newly -diagnosed disease.
Novartis Confidential Page 13
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Patient An individual with the condition of interest
PeriodA minor subdivision of the study  timeline; divides phases into smaller 
functional segments such as screening, baseline, titration, washout, etc.
Premature subject 
withdrawalPoint/time when the subject exits from the study  prior to the planned 
completion of all study drug administration and assessments; at this 
time all study  drug administration is discontinued and no further 
assessments are planned.
Randomization 
numberA unique identifier assigned to each randomized subject, 
corresponding to a specific treatmen t arm assignment
Screen Failure A subject who is screened but is not treated or randomized
StageA major subdivision of the study  timeline; begins and ends with major 
study  milestones such as enrollment, randomization, completion of 
treatment, etc.
Study completionPoint/time at which the subject came in for a final evaluation visit or 
when study  drug was discontinued whichever is later.
Study  drug 
discontinuationPoint/time when subject permanentl y stops taking study  drug for any 
reason; may or may notalso be the point/time of premature subject 
withdrawal.
Study  
drug/treatmentAny drug (or combination of drugs) administered to the subject as part 
of the required study  procedures; includes investigational drug, active 
drug run -ins or background therap y.
Study  treatmentAny drug administered to the study  participants as part of the required 
study  procedures; includes investigational drug (s), control(s) or non-
investigational medicinal product(s)
Study  treatment 
discontinuationWhen the subject permanently  stops taking study treatment prior to the 
defined stud y treatment completion date
Subject A trial participant (can be a healthy  volunteer or a patient)
Subject numberA unique number assigned to each subject upon signing the informed 
consent. This number is the definitive, unique identifier for the subject 
and should be used to identify  the subject throughout the study  for all 
data collected, sample labels, etc.
Treatment numberA unique identifier assigned in non-randomized studies to each dosed 
subject, corresponding to a specific treatment arm 
Novartis Confidential Page 14
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
VariableA measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested 
in the study
Withdrawal of 
consent (WoC)Withdrawal of consent from the study  is defined as when a subject 
does not want to participate in the study  any longer, anddoes not want 
any further visits or assessments, anddoes not want any further study 
related contact, and does not allow analy sis of alread y obtained 
biologic material
Novartis Confidential Page 15
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Commercially Confidential Information
Novartis Confidential Page 16
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Commercially Confidential Information
Novartis Confidential Page 17
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Commercially Confidential Information
Novartis Confidential Page 18
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Commercially Confidential Information
Novartis Confidential Page 19
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Commercially Confidential Information
Novartis Confidential Page 20
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Commercially Confidential Information
Novartis Confidential Page 21
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Commercially Confidential Information
Novartis Confidential Page 22
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Commercially Confidential Information
Novartis Confidential Page 23
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Protocol sy nopsis
Protocol number CACZ885X2206
Title A multiple-dose, subject -and investigator -blinded, placebo -controlled, parallel 
design study  to assess the efficacy, safety  and tolerability of ACZ885 
(canakinumab) in pediatric and young adult patients with sickle cell anemia.
Brief title Study of efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric 
and young adult patients with sickle cell anemia.
Sponsor and 
Clinical Trial 
PhaseNovartis
Phase II
Intervention type Drug
Study type Interventional 
Purpose and 
rationaleThis study is designed to assess if inhibition of IL-1β by canakinumab will reduce 
daily pain in association with attenuation of intravascular inflammation in pediatric
and young adult patients with sickle cell anemia, therefore allowing further 
development of the compound for treatment of t his disease population.
A pediatric and young adult population ( 8-20 years of age) is chosen because the 
patients are more likely to be without significant accumulated, SCA-related 
co-morbidities and are most likely to benefit from the compound’s mechanism of 
action. Moreover, canakinumab has been widely studied in inflammatory  diseases 
involving pediatric populations that encompass the age range proposed in this 
study, with an estimated 528 pediatric patients <1 to 17 years exposed to 
canakinumab treatment in Novartis -sponsored intervent ional studies as of 
30June 2017. Among the inflammatory  diseases involving pediatric patients for 
which canakinumab has received health authority approvals include sJIA and 
CAPS for patients ≥2 years and ≥4 years, respectiv ely.
The dose of canakinumab selected for the current proof -of-concept trial is 300 mg 
s.c. (4 mg/kg for patients ≤40 kg), monthly. This dosing regimen is predicted to
achieve and maintain suppression of the inflammation over time, allowing for
tissue repa ir and reductions in pain and crisis frequency.
Stratification is planned for patients at treatment randomization according to 
presence or absence of concurrent hydroxyurea use because this standard -of-
care therapy has potential therapeutic benefits against the disease, but its 
practical use in pediatric populations remains limited.
The rationale for the additional safety visit 8 weeks after the final clinical 
assessment at Week 48 is to monitor for any potential, late appearing AEs after 
having terminated treatment.
The opportunity for continued, open label treatment is provided in this study 
design to allow participants from the placebo -treated arm the option for receiving 
active treatment and for those in the active treatment group to continue on 
treatment, thus providing additional exposure data and evidence for sustained 
efficacy  in this patient population in which canakinumab is envisaged as a long 
term treatment.
Novartis Confidential Page 24
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Prima ry 
Objective(s)To determine the effect of canakinumab versus placebo on daily pain experienced 
by sickle cell anemia patients (Reduction of average daily pain VAS over the 
period of Week 8 to 12 as compared to baseline levels).
Secondary 
Objectives-Todetermine the duration of effects of canakinumab versus placebo on daily 
pain experienced by SCA patients (Reduction of average daily pain VAS over 
4-week intervals up to Week 24 as compared to baseline levels )
-To determine the effect of canakinumab versus placebo on laborator y markers 
of inflammation (W eek 12 versus baseline of: serum hsCRP, W BC count, 
Absolute counts of blood neutrophils, Absolute counts of blood monocytes).
-To determine the effect of canakinumab versus placebo on laborator y and 
functional markers of hemolysis.
-To determine the effect of canakinumab versus placebo on SCA -related day s 
missed from school or work
-    To determine the effect of canakinumab versus placebo on reducing the need 
foracute blood transfusion
-To assess the safety  and tolerability of canakinumab in patients with SCA as 
measured by adverse events (AEs), including immunogenicity as indicated by 
the presence of anti -drug antibodies
-To determine the PK of canakinumab in SCA patients
Study design This study is an ambulatory -based study  of 24 weeks duration followed by an 
additional 24-week open label phase and is subject -and investigator -blinded, 
randomized, placebo -controlled, parallel group, non-confirmatory  to assess the 
clinical efficacy of canakinumab administered s.c. in 6 injections given 28 days 
apart (monthly injections ). This study will randomize approximately 60 pediatric 
and young adult patients (targeting 48 completers) diagnosed with SCA who 
experience chronic or episodic pain, i.e., detectabl e average daily pain level over 
a 1-2 week screening period and ≥2painful episodes in the past year of likely 
sickle cell etiology requiring analgesia and interfering with the patient’s normal 
daily routine .
Population This study will recruit patients ,8 to 20 years of age (both inclusive) with SCA .
Key Inclusion 
criteria-Male and female subjects , 8-20 years of age (both inclusive) diagnosed with 
sickle cell anemia (HbSS) or sickle beta0thalassemia (documented by family 
studies, or analy sis of either hemoglobin or DNA).
-Patient’s written informed consent from those ≥18 years of age must be 
obtained before any assessment is performed. Parent or legal guardian’s 
written informed consent and child’s assent, if appropriate, are required before 
any assessment is performed for patients < 18 years of age.
-Detectable baseline of background or episodic pain measured by daily e -diary 
over 1 to 2 weeks during screening period as defined below: 
Average daily pain score ≥ 1 cm without analgesic use over a period of at least 
7days and/or,
At least one episode of pain requiring analgesic use during a period of up to 
14days.
-History of ≥2vaso -occlusive pain episodes in the past year, as defined as pain 
with no other, non -sickle cell identifiable cause that requires analgesia and 
interferes with the patient’s normal daily routine.
Novartis Confidential Page 25
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Key Exclusion 
criteria-History of known anaphylaxis or hypersensitivity to canakinumab or any
component thereof .
-Ongoing or treatment within the past 3 months with red blood cell transfusion
therapy, or have evidence of iron overload requiring chelation therapy.
-Transcranial Doppler ultrasound in the past year or at screening
demonstrating velocity in middle or ant erior cereb ral or internal carotid arter y
≥200 cm/sec. Note, t ranscranial Doppler (TCD) assessment is only required in
patients for whom the trans -temporal acoustic window is sufficient for imaging
the cranial arteries.
-Administration of any other blood products within 3 weeks prior of screening
visit.
Study treatment The dose of canakinumab selected for the current proof -of-concept trial is 300 mg 
s.c. monthly (4 mg/kg for patients ≤40 kg),
Efficacy/PD 
assessments-Reduction of average daily pain VAS over the period of Week 8 to 12 as
compared to baseline levels
-Reduction of average daily pain VAS over 4 -week intervals up to W eek 24 as
compared to baseline levels
-Serum hsCRP, W BC count, a bsolute counts of blood neutrophils, a bsolute
counts of blood monocytes, hemoglobin concentration, reticulocyte count,
haptoglobin, LDH, bilirubin (total, direct and indirect) ,
.
Key safety 
assessments-Adverse events,
-
Other 
assessments
Data analysis The post-baseline average daily pain VAS (visual analog scale) will be calculated 
for each dose from the start o f the dose till the day before the next dose, i.e. ,in an 
averagely 4-week interval (e.g., Week 0-4, Week 4-8, etc., depending on the 
actual dosing days). The baseline average pain VAS will be calculated as the 
average of daily pain scores from screening up to pre-dosing over a period of at 
least 7 days. Reduction from baseline in the average daily pain VAS, i.e., baseline 
minus post -baseline, will be analy zed using a Bayesian model for repeated 
measures using Proc MCMC in SAS. The model includes baseline average daily 
pain score as a continuous covariate; treatment group, timeandhydroxy urea use 
history (Yes/No) as fixed factors. Interactions of time by treatment group and time 
by baseline covariates will also be included in the model. Non-informative priors 
will beused for the fixed effects and weakly informative prior, for the covariance. 
Unstructured covariance structure will be used and other covariance structure will 
be investigated if there is convergence problem . Interaction of hydroxyurea use 
and treatment group will be explored via visualizations; if substantial interaction is 
suspected it will be further explored by including this interaction term in the whole 
model.
A comparison of canakinumab 300 mg s.c. versus placebo for the period of W eek 
8-12 is of primary interest. Data up to Week 12 will be included in the primary
model. Bayesian posterior probabilities will be used to assess the following PoC
criteria as a guidance for decision making:
Prob (the reduction of average pain score over the period of Week 8-12 in 
canakinumab is greater than Placebo) > 90%, and
Prob (the reduction of average pain score over the period of Week 8-12 in 
Commercially Conf idential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 26
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
canakinumab is greater than Placebo by 1) > 50%.
The target difference of 1 is chosen based on the literature s earch on the 
Minimally Clinical Important Difference (MCID) in pain studies.
Data up to Week 24 will also be analyzed with the same model specifications 
when there are at least about 50% completers at Week 24 and also upon the 
study completion. Pain data in the open label when available will also be 
summarized, visualized and explored in appropriate statistical models, to evaluate 
the maintenance of the efficacy  in patients randomized to canakinumab group 
and/or improvements in patients randomized in placebo group.
Patients who have missed two consecu tive dosing or more in the blinded 
treatment period or have other protocol deviations severely affecting the 
evaluation of efficacy  will be excluded in the primary efficacy  analysis for the 
blinded period. This is the primary PD analy sis set.
Key words ACZ885, canakinumab, adolescent ,sickle cell anemia
Commercially Confidential Information
Novartis Confidential Page 27
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
1 Introduction
1.1 Background
Sickle cell anemia (SCA )
SCA is a life-long disease with high morbidity  and mortality . This inherited disease is the 
most common hemoglobinopathy  and is caused by a single amino a cid change in the β -globin 
chain that results in structurall y abnormal hemoglobin S, or by compound heteroz ygosity for 
hemoglobin S and another β-globin chain abnormali ty, typicall y hemoglobin C or 
β-thalassemia. These mutations lead to abnormally  shaped sickle cell erythroc ytes with 
reduced membrane elasticity  with increased propensity  for lysis and adherence. Heterozy gous 
individuals carrying one copy  of the mutation (sickle cell trait) usuall y have no overt disease, 
but those homozy gous for the mutation can experience disease severity  and potential 
complications to varying extents, dependent on the proportion of red blood cells affected, 
other, coexisting conditions such as G6PD deficiency  or thalassemia, and exposure to 
environmental factors such as infe ction, deh ydration and acidosis that favor sickling.
There are an estimated 312,000 people homozygous for hemoglobin S (hemoglobin SS, 
HbSS) born each year throughout the world (Saraf et al 2014). Global distributions of 
newbo rns with the disease are 60% in sub
-Saharan Africa, 20% in Arab -Indian regions, 7% 
inthe Americas and 5% in Eurasia. There are about 20-25 million individuals world -wide 
who have homozy gous sickle cell disease, 
including 12 -15 m illion in sub-Saharan Africa, 
5-10 million in India and about 3 million scattered about elsewhere in the world. Due to the 
similar historical distribution patterns of malaria and of hemoglobin S, it has been proposed 
that protection from malaria provided a heterozy gote advantag e for these mutations in 
selected populations. Subsequent migration patterns have distributed sickle cell genes into 
regions not endemic for malaria.  About 8% of African Americans carry the sickle gene and 
100,000 live with SCA. However, they are responsi ble for >70,000 annual hospitalizations 
(Kauf et al 2009). Among SCA patients the median age at death is 42 y ears in Western societ y 
and half that age in less developed countries.
Clinical manifestations of the disease include chronic inflammation, acute and chronic pain, 
fatigue and chronic hemoly tic anemia with recurrent vaso-occlusive crises. Thus, patients 
experience chronic signs and symptoms of their disease throughout life, punctuated by 
episodic crises, together resulti ng over time in severe end-organ damage and early mortality . 
Children and adults with SCA have an overall reduced qualit y of life. Chronic fatigue also 
plays a role in reduced quality  of life in SCA patients and is associated with acute care visits 
for pain as well as school absences and missed caregiver workday s (Dampier et
al2010, 
Panepinto et al 2014 ). O
ther known complications of the disease include stroke, osteonecrosis,
nephropath y, pulmonary disease, retinopathy , priapism and reduced cognition. The spleen is 
frequentl y affected early in life due to repeated infarctions, leading to increased susceptibility 
to infections by  encapsulated organisms.
Novartis Confidential Page 28
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Treatment options for SCA are quite limited, with hydration, analgesia and antibiotics used 
for management of acute SCA crises. Hydroxyurea (ribonucleotide reductase inhibitor), first 
synthesized in 1869, is approved in the US and in the EU for SCA and is used to reduce 
frequency  of crises by increasing the proportion of fetal hemoglobin over the mutated sickle 
form. However, hydroxyurea remains underutilized by SCA patients and their physicians due 
to uncertainties regarding associated toxicities. This cytostatic drug has a wide range of 
potential AEs that include bone marrow toxicity  and potential increased leukemia risks and 
thus requires close monitoring. L-glutamine (Endari™) is approved in the USto reduce the 
acute complications of SCAin adult and pediatric patients 5 years and older. Another SCA 
therap y is frequent blood transfusions to reduce the proportion of sickle -prone RBCs in 
circulation. The only known potential cure for SCA is bone marrow transplantation which has 
proven effective in children but its potential long term toxicities limit use to only the most 
severel y affected patients. Therefore, alternative therapeutic targets and disease mechanisms 
should be considered in this disease.
Evidence for chronic intravascular inflammation in sickle cell disease
Due to increased hemoly sis of the abnormal, sickled red blood cells, SCA patients have 
constitutively  high levels of circulating hemoglobin /heme that exhausts the body ’s protective 
scavenger capacit y, driving acute on chronic inflammation under sterile or infectious 
conditions. High levels of C
-reactive protein (CRP) and other inflammation mediators such as 
IL-1β, IL-6, IL-17, IL-18 and TNF -α are common in SCA. Increas ed levels of IL-1β and 
IL-18 trigger endothelial cell activation, upregulati on of adhesion molecules and neutrophil 
activation (Dina rello 1999; Morel et al 2001 ;Gerdes et al2002 ). Acute crises arise from 
increased adhesive interactions betw een sickled RBCs and leukocy tes with endothelial cells, 
triggered by stressors such as dehydration or otherwise mild viral infections, causing vascular 
obstruction and tissue ischemia. A vicious, positive feedback cycle of inflammation ensues, 
resulting in marked pain and end organ damage.
The inflammasome is a multiprotein oligomer that is expressed in myeloid cells as a 
component of the innate immune system. Inflammasomes can be triggered by a  variety of 
activators and processes, resulting in an inflammat ory cascade that includes cleavage by 
caspase -1 of pro-IL-1β and pro-IL-18 into their active forms, along with triggering of other 
inflammatory  processes. Over the last few years, there has been an increasing body  of 
literature about the efficacy  of target ing IL-1β in a wide spectrum of autoinflammatory 
conditions. Autoinflammatory  disorders can be distinguished from autoimmune disorders by 
disease mechanisms involving innate immune regulation of cytokines and neutrophilic 
inflammation rather than adaptive immune responses involving antibodies and lymphocy tes. 
Inflammasome -mediated diseases include rare orphan diseases classified together within the 
condition of hereditary  periodic fevers. Another disease in which the inflammasome plays a 
key role is gouty arthritis. These conditions have in common either conditions or mutations 
that result in increased inflammasome activation, resulting in chronically  recurring 
inflammation.
Novartis Confidential Page 29
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Sickle cell anemia as an inflammasome -mediated disease
Recent literature evidence has identified SCA to have a strong inflammasome- driven 
component via high rates of constitutive intravascular hemoly sis that overwhelm the 
scavenger capacity  of the body  for heme and free iron, resulting in chronic activation of 
endothelial cells and vascular inflammation. In mouse models, heme induces IL-1β 
production and neutrophil migration dependent on caspase -1 cleavage, thus demonstrating 
inflammasome activation (Dutra et al2014 ). In the same report, the hemoly sis-induc ed 
lethality  in an animal model was greatly  reduced in Nlrp3 -, Asc -and caspase -1-deficient mice, 
indicating inflammasome involvement. Transgenic SCA animal models largel y recapitulate 
human pathophy siology , with subclinical inflammation and increased neut
rophil counts as 
well as elevated soluble vascular adhesion molecules (Cain et al2012 ). Anti- IL-1β antibody 
treatment in another transgenic SCA mouse model markedl y ameliorated intravascular flow 
impedance induced b y hypoxia (Kaul and Gram 2011)
.
Therapeutic targeting of IL- 1β in sickle cell disease
IL-1β is recognized as one of the principal pro-inflammatory  cytokines in a variety  of 
inflammatory  conditions, including those involving autoinflammatio n and the inflammasome 
(Church et al 2008). This cytokine is produced by a  variety of cell types, particularl y 
mononuclear phagocytes, in response to injury , infection and inflammation.
ACZ885 (canakinumab) is a high affinity , fully human, monoclonal anti-human interleukin -
1β (IL-1β) antibody  of the IgG1/κ isotype that is designed to bind to human IL-1β, blocking 
the interaction of this cy tokine to its receptors, thus functionally  neutralizing the bioac tivity  of 
this cy tokine.
Canakinumab is currently  registered in more than 70 countries worldwide under the name 
Ilaris®. Depending on countries, Ilaris is approved for treatment of adults and children aged 
2years and older that have a condition known as cryopyrin-associated periodic syndromes 
(CAPS), including familial cold autoinflammatory  syndrome (FCAS) /Familial Cold 
Urticaria (FCU) , Muckle -Wells syndrome (MWS) and Neonatal -Onset Multisy stem 
Inflammatory  Disease (NOMID) / Chronic Infantile Neurologica l, Cutaneous, Articular 
Syndrome (CINCA) . Additional monogenetic periodic fever syndrome sfor which Ilaris®has 
received approvals include tumor necrosis factor receptor -assoc iated periodic syndrome 
(TRAPS), colchicine -resistant/intolerant familial Mediter ranean fever (crFMF) and hyper-
Immunoglobulin D Syndrome with periodic fever syndrome (HIDS) /Mevalovate Kinase 
Deficiency  (MKD) (Rigante 2016). Ilaris®is also approved for the treatment of active 
systemic juvenile idiopathic arthritis (sJIA) in children 2 years of age and older and in Europe 
for the symptomatic treatment of acute gouty  arthritis attacks. For further details please refer 
to the I nvestiga tors Brochure (IB).
The above evidence supports that inflammasome activity  is constitutively  upregulated in 
sickle cell anemia patients and may play a role in disease activity . Thus, IL-1β pathway 
interruption with canakinumab is anticipated to confer ther apeutic benefit.
Novartis Confidential Page 30
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
1.2 Nonclinical data
1.2.1 Teratogenicity  and reproductive toxicity  data
1.3 Clinical data
1.3.1 Human safety  and tolerability  data
As of 30 June 201 7, an estimated 10,939 patients, of which 528 pediatric patients aged <1 to 
17 years,have received canakinumab treatment in 74 Novart is-sponsored investigational 
clinical trials and 1 6third part y, investigator -initiated trials in a wide spectrum of diseases
where IL-1β play s a role, such as cry opyrin-associated periodic s yndromes (CAPS), mild 
asthma, psoriasis, wet age-related macular degeneration (AMD), gout y arthritis, ty pe 2 
diabetes mellitus, atherosclerosis, rheumatoid arthritis (RA), and sy stemic juvenile idiopathic 
arthritis (sJ IA). Health authority  approvals for Ilaris have been granted for monogenetic 
periodic fever s yndromes, including 
CAPS, TRAPS hyper-Immunoglobulin D Sy ndrome with 
periodic fever s yndrome (HIDS)/ Mevalovate Kinase Deficiency  (MKD) , colchicine -
resistant/intolerant familial Mediterranean s yndrome (crFMF), gout and sJIA. The post-
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 31
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
marketing cumulative patient exposure since the first launch of the product is estimated to be 
approximately  15,260 patient treatment- yearsas of 30 June 2017 year. The doses 
administered i.v. ranged from 0.3 mg/kg to 10 mg/kg or a fixed dose of 600 mg, and from 0.5 
mg/kg to 9 mg/kg s.c. or fixed doses of 5 mg to 300 mg s.c. ACZ885 has a long half -life 
averaging approximately  4weeks in man andmonthly  s.c. dosing of 4 mg/kg up to 300 mg is 
approved b y the FDA and EMA for sJIA. The frequency  of dosin g ranged from a single dose 
to quarterl y repeated administration. 
Pediatric patients and those patients with a severe CAPS 
phenoty pe may  require higher than usual doses to attain full clinical response, and current 
labeling for canakinumab allows for dose escalation up to a maximum of 8 mg/kg for patients 
≤40 kg and to 600 mg for patients >40 kg. Patients with sy stemic juvenile idiopathic arthritis 
(SJIA) also tend to require higher dosing of canakinumab for adequate response. These 
indications encompass a relativel y comparable patient population to the ACZ885X2206 
patient population in terms of age range and inflammatory levels. In registration and post -
registration studies for canakinumab in this indication, there were no differences observed in 
the incide nce of overall AEs across the different dosing groups, including those receiving 
either 150 mg or 300 mg s.c. m onthly .
Studies in adult RA patients have been treated with 300 mg s.c. up to 184 weeks (studies 
CACZ885A2201, -E1 and -E2) at every  2  w eeks for the first 12 weeks and every  4weeks 
thereafter. The 300 mg dosing regimen was well-tolerated, without dose-dependent 
differences in AE incidence compared to every 4 weeks s.c. dosing of 150 mg.
Overall, the development program with ACZ885 has demonstrated a good safet y and 
tolerability  profile as evidenced by 1) a low number of study  discontinuations for AEs, 
predominantly  mild injection site reactions, and 2) no specific target organ toxicity . The AE 
profile is characterized by  non-specific gastrointestin al and central nervous sy stem events and 
infections predominantly of the upper respiratory  tract, in some instances serious, with all 
infections responding to standard therapy .Thedetails of the SAEs and AEs of the completed 
studies and relevant details of the SAEs of the ongoing studies are summarized in the latest 
version of the IB. Adverse events in unblinded studies ranged from mild-to-moderate in 
severit y and include upper respiratory  tract infections, nasophary ngitis and otitis, headache, 
nausea, dia rrhea, and asthenic conditions. So far the maximum median duration of exposure to 
canakinumab is more than 4years for the first 4MWS patients enrolled in the 
CACZ885A2102 trial.
Similar to patients with monogenetic periodic fever syndromes, patients suffering from sickle 
cell anemia also have chronic inflammation and elevated serum levels of C-reactive protein 
and IL-1β (Akohoue et al 2007; Qari et al 2012 ) with recurrent periodic crises involving 
further, elevations of inflammation and serum CRP (Mohammed et al 2010;
Kanavaki et
al2012). In a recently  completed, large clinical trial involving pediatric and 
adult patients with periodic fever syndromes (CACZ885N2301 ), insufficient or non-response 
to initial canakinumab dosing at 150 mg resulted 
in further dose escalation to 300 mg/month 
in 16% of patients with crFMF, 32% of patients with HIDS and 36% of patient with TRAPS. 
In those patients, canakinumab dosed at 300mg s.c. monthl y was shown to bind additional 
IL-1β along with increased responder rates over rates observed with monthly  s.c. dosing at 
150 mg (i.e., crFMF +9.7%, HIDS +21.6%, TRAPS +27.3%). Similar improvements with 
increased monthly  dosing of 300 mg versus 150 mg were also seen in secondary  outcomes 
(i.e., physician global assessment of disease activity , serum reductions of acute phase 
Novartis Confidential Page 32
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
reactants) . Thus, these results sugg est that canakinumab dosing at 300 mg binds additional 
target and is more clinically  effective than 150 mg dosing in patients with more severe 
inflammation.
1.3.2 Human pharmacokinetic data
Canakinumab has the expected pharmacokinetics of an IgG1 -type antibody with a low volume 
of distribution (VSS=6.0 L) and low clearance. The serum clearance (CL) of canakinumab 
varied according to body  weight (e.g., CL=0.174 L/day in aCAPS patient of body  weight 
70kg, 0.11 L/day  in a SJIA patient of body  weight 33 kg and 0.23 L/day  in a gout patient of 
body  weight 93 kg). Half-lives vary between 21 and 30 days. Within the dose range studied, 
the pharmacokinetics of canakinumab were linear. The systemic 
exposure parameters, 
AUC and Cmax, increase in proportion to dose over thedose range of 0.30 to 10.0 mg/kg 
given as i.v. infusion and from 150 mg to 300 mg when administered as an s.c. injection. 
Theabsolute bioavailability  ofs.c. canakinumab is 70%. After accounting for body  weight 
differences, no clinically  significant differences in the pharmacokinetic properties of 
canakinumab were observed between CAPS, SJIA and gouty arthritis patients. 
Furthermore, with body weight -based dosing, canakinumab administered in pediatric 
indications (e.g., CAPS and SJIA) was observed to be simila r in various age subgroups. 
Forinstance, in SJIA patients, exposure parameters corrected for body  weight (such as AUC 
and Cmax) were comparable across age groups from 2 to <20 years following subcutaneous 
administration of canak inumab 4 mg/kg every  4weeks. Amathematical model to characterize 
the binding kinetics of canakinumab to IL-1β has been created. The model successfull y fits 
the patient data and allows estimation of canakinumab clearance and volumes of distribution, 
together with IL -1β rate of release and half- lives.
1.3.3 Human pharmacody namic data
Canakinumab binds to and inactivates IL -1β and blocks downstream events of IL -1β signaling, 
including IL-1β production, IL-1β pathway -related gene activation, elevation of acute phase 
proteins, such as serum amyloid A (SAA) and C-reactive protein (CRP), and mobilization of 
neutrophils and platelets from bone marrow.
Normally  undetectable, serum IL-1β becomes detectable in humans when complexed with 
canakinumab. These IL-1β/canakinumab complexes are biologi cally inactive and have been 
utilized in all clinical studies as a surrogate PD marker because their increase reflects the 
reduction of free IL-1β levels caused b y binding to canakinumab.
1.4 Stud y purpose
This study  is designed to assess if inhibition of IL-1β by canakinumab will reduce daily pain 
in association with attenuation of intravascular inflammation in pediatric and young adult 
patients with sickle cell anemia, therefore allowing further development of the compound for 
treatment of this disease popula tion.
Novartis Confidential Page 33
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
2 Study  objectives and endpoints
2.1 Primary  objective(s)
Primary objective(s) Endpoints related to primary objective(s)
To determine the effect of ACZ885 versus
placebo on dail y pain experienced b y
sickle cell anemia patientsReduction of average daily  pain VAS
over the period of Week 8 to 12 as
compared to baseline levels
2.2 Secondary  objective(s)
Secondary objective(s) Endpoints related to secondary objective(s)
To determine the duration of effects of
canakinumab versus placebo on daily  pain
experienced b y SCA patientsReduction of average daily  pain VAS
over 4 -week intervals up to Week 24 as
compared to baseline levels
To determine the effect of canakinumab
versus placebo on laboratory  markers of
inflammationWeek 12 versus baseline of:
Serum hs -CRP
WBC count
Absolute counts of blood neutrophils
Absolute counts of blood monocy tes
To determine the effect of canakinumab
versus placebo on laboratory  and
functional markers of hemoly sisWeek 12 versus baseline of:
Hemoglobin concentration
Reticulocy te count
Haptoglobin
LDH
Bilirubin (total, direct and indirect)
Oxygen percent saturation (SaO2)
To determine the effect of canakinumab
versus placebo on SCA -related days
missed from school or workNumber of day s absent from school or
work due to pain as recorded by  daily  e-
diary
To determine the effect of canakinumab
versus placebo on reducing the need for
acute blood transfusionThe rate of SCA -related acute
transfu sion
To assess the safet y, including
immunogenicit y, and tolerability of
canakinumab in patients with SCA as
measured b y adverse events (AEs)Adverse events in patients taking
ACZ885 compared to placebo up to a
total of 56 weeks treatment.
To determine the PK of ACZ885 in SCA
patientsSerial serum PK determinations in
patients with SCA
Novartis Confidential Page 34
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
2.3 Exploratory  objective(s)
Commercially Confidential Information
Novartis Confidential Page 35
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
3 Investigational plan
3.1 Stud y design
This study  (Figure 3-1) is an ambulatory -based study  of 24 weeks duration followed by an 
additional 24-week open label phase and is subject -and investigator -blinded, randomized, 
placebo
-controlled, parallel group, non-confirma tory to assess the clinical efficacy  of 
canakinumab administered s.c. in 6 injections given 28 days apart. This study  will randomize 
approximately  60 pediatric and young adult patients (targeting 48 completers of 8 to 20 years 
old) diagnosed with SCA who experience chronic or episodic pain, 
i.e., detectable average 
daily  pain level over a 1-2 week screening period and at least 2 painful episodes in the past 
year of likely sickle cell etiology  requiring analgesia and interfering with the patient’s normal 
daily routine .
Figure 3-1 Study  design
Acceptable prior established background therapy  includes hydroxyurea and supportive 
antibiotic and analgesic medications. Patients will be randomized to either ACZ885 treatment 
or placebo treatment in a 1:1 ratio, with treatment stratification based on concurrent 
hydroxyureatherapy  (yes/no).
Subjects who are prematurel y withdrawn from the study  for reasons other than safet y or lack 
of efficacy  will be replaced on a case-by-case basis. Re-screening of subjects may be allowed 
under the guidance of the Sponsor’s medical expert.
For each subject, there will be a maximum 28 -day screening period that will include recording 
of daily  pain freque ncy and intensity  by e-diary  for at least 1 week.
Commercially Confidential Information
Novartis Confidential Page 36
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Subjects who meet the eligibility  criteria at screening will undergo evaluation of full baseline 
clinical and biomarker assessments prior to first dose administration. The screening daily  pain 
results will be used to derive the baseline value for this prim ary endpoint of average daily pain. 
All safet y evaluations must be available prior to dosing and results must demonstrate all 
eligibility  criteria are met. Enrolled subjects will be randomized at a 1:1 ratio to receive 
treatment with either canakinumab or placebo with stratification based on concurrent 
hydroxyureatherapy . On Day 1, monthl y s.c. dosing with canakinumab will begin at 4mg/kg 
for patients weighing ≤ 40 kg and 300 mg for all other patients. Patients in the placebo 
treatment arm will be injecte d in a like manner with placebo. All patients will return to the 
study  centers for safet y checks on a monthl y basis when they will receive treatment with 
either canakinumab or placebo. Additionall y, patients will undergo clinical and laboratory 
evaluations as outlined in the Assessment Schedule every  28 days. The final blinded dosing 
will take place on Week 20, followed by blinded clinical assessments at Week 24. Patients 
from both study  arms are then offered optional, open label monthly  dosing of ACZ885 for an 
additional 24 weeks (Weeks 24-48), with clinical outcomes again assessed according to the 
Assessment schedule .  Patients return for the end of study  (EOS) visit at Week 56.For 
patients who choose not to participate in the optional, open label portion of the study , or for 
patients stopping treatment early for any other reason, an E
OS visit will occur approximately 
8 weeks after last dose received.
The EOS for an individ ual patient is defined as the EOS visit described above, which will 
occur approximately  8 weeks after last dose received. The global EOS is defined as the EOS 
visit of the last patient in the trial perfo rming the EOS . 
A follow -
up visit or phone call for SAEs must be performe d 8 weeks following 
end-of-treatment visit or early discontinuation, or 8 weeks after last injection of study  drug, 
whichever is later. If anaphy lactic reactions occur after injection, two more immunogenicit y 
samples (at the time of the event and 8 weeks later) need to be taken.
3.2 Rationale of study  design
A randomized, placebo- controlled, subject and investigator blinded approach is used to 
eliminate potential bias in reporting safet y and clinical efficacy  data in this first exploratory 
study  in SCA patients.
Apediatric and young adult population is chosen because those patient s are more likely  to be 
without significant accumulated, SCA -related co-morbidities and are most likely  to benefit 
from the compound’s mechanism of action. Moreover, canakinumab has been widel y studied 
in inflammatory  diseases involving pediatric populations that encompass the age range 
proposed in this study , with an estimated 528 pediatric patients <1 to 17 years exposed to 
Commercially Confidential Information
Novartis Confidential Page 37
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
canakinumab treatment as of 30 June 201 7. Inflammatory  diseases involving pediatric patients 
for which canakinumab has received healt h authority  approvals include sJIA and CAPS for 
patients ≥2 years and ≥4 years, respectively . Because levels of inflammation tend to increase 
during the course of childhood in SCA patients, this initial, early  phase study  will focus on 
pediatric and young adult patients of ages 8-20 years to increase the likelihood of detecting 
beneficial effects with an anti- inflammatory  intervention.
Stratification is planned for patients at treatment randomization according to presence or 
absence of concurrent hydroxy ureause because this standard -
of-care therap y has potential 
therapeutic benefits against the disease, but its practical use in pediatric populations remains 
limited.
High -sensitivity  C-reactive protein (hs-CRP) is a marker that directl y correlates with long 
term morbidity  (van Beers et al 2015 ) and is part of this stu dy's inclusion criteria. The hs-CRP 
threshold value of ≥1.0 mg/L  used in this study 's inclusion criteria is based on evidence from 
the literature that the25
-75 percentile value range of hs-CRP across a large, cross -sectional 
African American adolescent population aged 10-15 years is 0.1-1.2 mg/L (Ford et al 2003). 
In contrast, the 25
-75 percentile value range of hs-CRP in children with HbSS/HbSβ0thal 
ranged from 1.02 -5.3 mg/L  (Krishnan et al 2010). Importantly , the sickle cell variant HbSC in 
this study  had lower hs -CRP values of 0.3 -1.2 mg/L, with correspondingly  reduced s
everity  of 
anemia and other clinical manifestations of the disease. In a second report 
(Akohoue et al 2007) serum CRP values of the majority  of HbAA adolescents (89%) were 
either <0.5 mg/L or not detectable, while i
n the stead y-state HbSS adolescents, 34% had CRP 
levels ranging between 1-5 mg/L and >50% had CRP concentr ations averaging 15.6 mg/L 
(5.7-52.6). Thus, the use of hs-CRP ≥1.0 mg/L in this study's inclusion criteria will ensure that 
enrolled patients have a minimal threshold of inflammation, an important therapeutic target of 
canakinumab.
The rationale for the additional safety  visit 8 weeks after the final clinical assessment at 
Week 48 is to monitor for any  potential, late appearing AEs after having termin ated treatment. 
More information may  be found in the Investigator’s Brochure.
The opportunit y for continued, open label treatment is provided in this study  design to allow 
participants from the placebo -treated arm the option for receiving active treatment and for 
those in the active treatment group to continue on treatment, thus providing additional 
exposure data and evidence for sustained efficacy  in this patient population in which 
canakinumab is envisaged as a long term treatment.
Novartis Confidential Page 38
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
3.3 Rationale for dose/regimen, route of administration and duration 
of treatment
3.4 Rationale for choice of comparator
3.5 Rationale for choice of background therapy
Not applicable.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 39
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
3.6 Purpose and timing of interim analy ses/design adaptations
3.7 Risks and benefits
Canakinumab has not been previousl y administered with therapeutic intent to patients with 
sickle cell anemia. Therefore, no statement can be made at this time on the actual clinical 
benefits of canakinumab in this patient population. However, given the mechanism of action 
of canakinumab and the relevant inflammatory  pathway s involving IL-1β as discussed in the 
background (Section 1.1), there is a reasonable expectation that a therapeutic response can be 
achieved with the compound in patients with sickle cell anemia.
Sickle cell anemia patients are at increased risk for infection, in part due to functional 
hyposplenism or from undergoing splenectomy  (Booth et al2010). This increased infection 
risk is primarily  confined to very  young children with the disease and is a major cause of early 
mortality  from the disease. The main pathogen of concern is S. pneumoniae , and risk for 
invasive streptococcal disease in SCA patients drops markedly with age. 
Preventative measures are considered the key strategy  in management of SCA infection risks. 
Optimal management of asplenic individuals includes life-long penicillin proph ylaxis and 
keeping vaccinations up-to-date. Additional preventative measures include meticulous 
attention to hand washing, cooking food thorough
ly, keeping perishable foodstuffs 
refrigerated, and avoiding contamination. Monitoring for early detection of infections is also 
important, with a low threshold for use of antibiotics.
Commercially Confidential Information
Novartis Confidential Page 40
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Hydroxyurea, approved for SCA in the EU and US,isa mutagenic chemotherap y drug 
associated with bone marrow toxicity  that requires close monitoring of blood counts and early 
recognition and treatment of infections. Thus there is precedence for the application of an 
immune suppressive treatment in this pa tient population.
Overall, the development program with canakinumab has demonstrated a good safet y and 
tolerability  profile as evidenced by a low number of study  discontinuations for AEs, 
predominantly  mild injection site reactions and no specific target organ toxicity . The AEs 
profile is characterized by  non-specific gastrointestinal and central nervous sy stem events, and 
infections 
predominantl y of the upper respiratory tract and urinary  tract infections, in some 
instances serious, with all infections responding to standard therapy . Patients may also 
experience reduction in leukocy te counts and thus will require close monitoring of their 
counts, in particular when receiving concomitant treatment with hydroxy urea. Treatment with 
canakinumab has a theoretica lly increased risk for opportunistic infections such as 
M.tuberculosis , but the actual frequency  remains unknown.
The available toxicology , efficacy , safet y, tolerability , overall low incidence of 
immunogenicit y (as represented by the presence of treatment-emergent anti-drug antibodies) 
and preliminary  efficacy  data in MWS, RA, sJIA and gouty arthritis, further support the 
clinical development of canakinumab in diseases in which IL-1β is likely  to have a 
predominant role. However, since preventing IL-1β re ceptor signaling may  alter immunologic 
responsiveness in unanticipated ways, patients receiving ACZ885 will be closely  monitored 
for clinical and laboratory  indicators of immune suppression and immune dysregulation, such 
as infection including opportunisti c infections (recognizing that blocking IL-1β may mask 
fever and blunt the inflammatory  response to infection), blood cells count abnormalities 
(including neutropenia), and development of malignancies, autoimmune manifestations and 
hypersensitivity  reactio ns.
Women of child bearing potential should be informed that taking the study  drug may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study  they must adhere to the contraception requirement for the duration 
of the study and up to 3 months after the last dose . If there is any  question that the subject will 
not reliably  comply , they should not be entered in the study .
There may  be unknown risks of canakinumab which may  be serious an d/or unforeseen.
3.7.1 Blood sample volumes
A maximum of 189 mL of blood is planned to be collected over a period of 12 months, from 
each subject as part of the study . Additional samples for monitoring of any safety  findings 
would be in addition to this. This is not considered to be a risk for this population.
Timings of blood sample collection are outlined in the Assessment Schedule, Section 8.1.
A summary  blood log is provided in the Site Operations Manual, toget her with instructions 
for all sample collection, processing, storage and shipment information.
See Section 8.9 regarding the potential use of residual samples.
Novartis Confidential Page 41
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
4 Population
This study  will recruit patients ages 8 to 20 years of age (both inclusive) with SCA, including 
hemoglobin SS and hemoglobin S
-β0thalassemia , as determined by family  studies, 
hemoglobin or DNA analy ses. A total of approximately  60 patients will be randomized to 
participate in the study . Re-evaluation of thesample size based on the variability  observed on 
the primary  endpoint and the discontinuation rate may be performed when the study 
approaches the first IA and the total enrollment will be capped at 90 ( Section 11.7 ).
The investigator must ensure that all subjects being considered for the study  meet the 
following eligibility  criteria. No additional criteria should be applied by the investigator, in 
order for the stud y population to be representative of al l eligible subjects.
Subject selection is to be established by checking through all inclusion/exclusion criteria at 
screening and first baseline prior to the first injection. A relevant record (e.g., checklist) of the 
eligibility  criteria must be stored wi th the source documentation at the study  site.
Deviation from an y entry criterion excludes a subject from enrollment into the study .
Patient re-screening will be allowed in the study  in the event of a delay  in treatment, e.g., in 
the event of a washout per iod of more than 28 days.
4.1 Inclusion criteria
SCA patients eligible for inclusion in this study  must fulfill allof the following criteria:
1.Male and female subjects ages 8-20 years of age (both inclusive) diagnosed with sickle 
cell anemia (HbSS) or sickle b eta0thalassemia (documented b y family studies, or anal ysis 
of either hemoglobin or DNA).
2.Patient’s written informed consent from those ≥18 y ears of age must be obtained before 
any assessment is performed. Parent or legal guardian’s written informed consen t and 
child’s assent, if appropriate, are required before any  assessment is performed for patients 
< 18 y ears of age.
3.
Detectable baseline of background or episodic pain measur ed by daily  e-diary  over 1 to 
2 weeks during screening period as defined below: 
-Average dail y pain score ≥ 1 cm without analgesic use over a period of at least 7 day s 
and/or,
-At least one episode of pain requiring analgesic use during a period of up to 14 day s.
4.History  of ≥2vaso-occlusive pain episodes in the past y ear, as defi ned as pain with no 
other, non- sickle cell identifiable cause that requires analgesia and interferes with the
patient’s normal dail y routine .
5.Patients on hy droxyurea therap y need stable dosing >60 day s prior to screening without 
signs of hem atological toxi cityand intention to remain on hydroxyureatherapy  throughout 
the initial 6 -month treatment period .
6.Screening hsCRP level ≥ 1.0 mg/L.
7.Full immunization status according to local guidelines against pneumococcus.
8.Able to communicate well with the investigator and to understand and comply  with the 
requirements of the study.
Novartis Confidential Page 42
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
4.2 Exclusion criteria
SCA patients fulfilling any  of the following criteria are noteligible for inclusion in this study :
1.History  of anaph ylactic reaction or known h ypersensitivity  to canakinumab , or an y 
component thereof .
2.Past history  of invasive serious pneumococcal disease, including sepsis, bacteremia, 
and/or meningitis. 
3.
Ongoing or treatment within the past 3 months prior to screening with red blood cell 
transfusion therap y, or have evidence of iron overload requiring chelation therap y.
4.Administration of any  other blood products within 3 weeks prior screening visit.
5.Uncontrolled liver disease or renal insufficiency , as defined b y the following:
elevated alanine aminotransferase (ALT) ≥ 3x ULN (if ALT at screening is >3x but 
<5xULN, a re -test will be allowed. If ALT at re -test is <3x UL N and confirmed at 
another re -test, the patient will be eligible for participation) . Chronic kidney  disease as per 
NKF stages ≥4: eGFR ≤29 mL /min/
1.73 m2.
6.Clinically  significant, abnormal vital sign data as judged b y the investigator and verified 
with repeated testing. 
7. Use of other investigational drugs at the time of enrollment, or within 5 half- lives of 
enrollment, or until the expected PD effect has returned to baseline, whichever is longer, 
or longer if required b y local regulations.
8.Prior treatment with an y biologic drug targeting the immune sy stem within 180 day s of 
randomization.
9.History  of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such 
abuse as indicated b y the laboratory assay s.
10.Any conditions or significant medical problems which in the opinion of the investigator 
immune compromise the patient and/ or places the patient at unacceptable risk for 
immunomodulat ory therapy , such as , but not limited to :
a.Absolute neutrophil count (ANC) <1,500/μl
b.Thrombocy topenia CTCAE v4.03 Grade 1: platelets <LLN (<100.0 x 109/L)
c.Any active or recurrent bacterial, fungal (with exception of ony chom ycosis) or viral 
infection
d.Presence of human immunodeficiency  virus (HIV) infection, active hepatitis B or 
hepatitis C infections based on screening lab results
e.Presence of active or latent tuberculosis (TB) or exposure risk established during 
screening such as, but not exclusively  to:
Close contact (e.g., share the same air space in a household or other enclosed 
environment for a prolonged period such as day s or weeks, but not minutes or hours ), 
with a person with active pulmonary  TB disease within the last y ear, or
Novartis Confidential Page 43
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Evidence of TB infection (active or latent) determined by  positive QuantiFERON test 
or positive purified protein derivative (PPD) test (≥5 mm induration) at screening or 
within 2 months prior to screening visit, according to national guidelines. If prese nce 
of TB infection is established then treatment for TB as per national guidelines must 
have been completed prior to randomization and definitive cure hasbeendemonstrated. 
In the absence of national guidelines, the following has been demonstrated: TB ha s 
been treated adequatel y by antibiotics, definitive cure can be demonstrated and risk 
factors resulting in TB exposure and contracting have been removed.
11.Live vaccinations within 3 months prior to study  drug dosing .
12.Current severe progressive or uncontrol led disease, which in the judgment of the clinical 
investigator renders the patient unsuitable for the trial.
13.Inability  or unwillingness to undergo repeated venipuncture (e.g., because of poor 
tolerability  or lack of access to veins).
14.Donation or loss of blood (amount depending on age and weight, 10 -20% or more of 
volume, within 8 weeks prior to first dosing, or longer if required b y local regulation.
15.History  of malignancy  of any  organ s ystem (other than localized basal cell carcinoma of 
the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless 
of whether there is evidence of local recurrence or metastases.
16.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female 
after conception and until the termination of gestation, confirmed by a positive hCG 
laboratory  test.
17. Transcranial Doppler ultrasound in the past y ear or at screening in patients with an 
accessible transtemporal window, demonstrating velocity  in middle or anterior cerebral or 
internal carotid artery  ≥200 cm/sec.
18.Female of child -bearing potential, defined as all women phy siologically  capable of 
becoming pregnant, unless they  are using basic methods of contraception during dosing of 
the investigational treatment and for up to three months after the last dose . Where basic 
contraception is sufficient for this study , abstinence should be encouraged in a pediatric 
population and if appropriate for sexually  mature adolescents and y oung adult, barrier 
methods should be advised and/or hormonal methods can be prescribed after careful 
evaluation b y a ph ysician.
Basic contraception methods include:
Total abstinence from heterosexual intercourse (when this is in line with the preferred 
and usual lifest yle of the subject). Periodic abstinenc e (e.g.
,calendar, ovulation, 
symptothermal, post- ovulation methods) and withdrawal are not acceptable methods 
of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectomy  or tubal ligati on at least six weeks before taking 
investigational drug.  In case of oophorectomy  alone, only  when the reproductive 
status of the woman has been confirmed b y follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female subjects on the 
study , the vasectomized male partner should be the sole partner for that subject.
Novartis Confidential Page 44
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Barrier methods of contraception: condom or occlusive cap (diaphragm or
cervical/vault caps). For UK: with spermicidal foam/gel/film/cream/vaginal
suppository
Use of oral, injected or implanted hormonal methods of contraception or other forms
of hormonal contraception that have comparable efficacy  (failure rate <1%), for
example hormone vaginal ring or transdermal hormone contraception or placement of
an intrauterine device (IUD) or intrauterine s ystem (IUS)
In case of use of oral contraception, women should have been stable on the same pill for a 
minimum of 3 months before taking stud y treatment.
Females within the age range of this study  are considered not of child bearing potential if 
they have had surgical bilateral oophorectom y (with or without hysterectomy ), total 
hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy  alone, 
only when the reproductive status of the woman has been confirmed by  follow up 
hormone level assessment is she considered not of child bearing potential.
No additional exclusions may  be applied by  the investigator, in order to ensure that the 
study  population will be representative of all eligible pat ients.
5 Restrictions for Study  Subjects
During recruitment, screening/informed consent review, and baseline visit, the subjects must 
be informed and reminded of the following restrictions:
5.1 Contraception requirements
Please refer to exclusion criteria ( Section 4 ) for details of contraception requirements for the study .
5.2 Prohibited treatment
Use of the treatments display ed in the table below are NOT allowed after the start of study 
treatment due to the concern for either increased potential immunosuppressant -related 
conditions or for potential impact on efficacy  assessments . These are prohibited for the 
duration of the stud y until 90 days after discontinuation of study drug.
Novartis Confidential Page 45
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Table 5-1 Prohibited treatment
Medication Action to be taken
Biologic drugs targeting the 
systemic immune sy stem (e.g., 
TNFα blockers, anakinra, rituximab, 
abatacept, tocilizumab)Discontinue study drug
Live vaccines (within 90 days of 
study drug dosing)Discontinue study treatment; if live vaccines are given after 
screening but prior to study drug administration, the subject 
may be enrolled after 90 days have passed since vaccine 
administration if the subject continue s to meet eligibility criteria 
upon rescreening
Systemic immune suppressive 
drugs, except for hydrox yurea 
maintained within a stable dosing 
regimen of >60 day s prior screeningDiscontinue study treatment if these medications are taken for 
more than 3 days . Maintain hydroxy urea at a stable dosing 
regimen throughout trial
Scheduled regular b lood 
transfusion therapyDiscontinue from study
5.3 Dietary  restrictions and smoking
There are no specific dietary restrictions.
5.4 Other restrictions
Not applicable.
6 Treatment
6.1 Stud y treatment
Details on the requirements for storage and management of study  treatment, and instructions 
to be followed for subject numbering, prescribing/dispensing and taking study  treatment are 
outlined in the Site Operations Manual.
6.1.1 Investigational treatment and control drugs
The investigational drug, ACZ885 (canakinumab) 150 mg and matching placebo liquid vials 
will be prepared b y Novartis and supplied to the I nvestigator as open labeled pack medication .
6.1.1.1 Bio-batch retention samples
Not applicable for this study .
6.1.2 Additional study  treatment
No additional study  treatment beyond investigational drug and control drug are included in 
this trial.
Novartis Confidential Page 46
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
6.2 Treatment arms
Subjects will be assigned to one of the following two treatmen t arms in a ratio of 1:1.
Study treatments are defined as:
During the blinded period: 
Monthly  doses of 300 mg (4 mg/kg for patients ≤ 40 kg) canakinumab s.c.
Monthly  doses of placebo to match the administered dose of canakinumab s.c.
During the open label period: 
Monthly  doses of 300 mg (4 mg/kg for patients ≤ 40 kg) canakinumab s.c.
6.3 Treatment assignment and randomization
Randomized treatment will be assigned to individual subjects by way of a randomization 
number .As stratification is planned for patients at treatment randomizat ion according to 
presence or absence of concurrent hydroxyureause, two randomization lists will be prepared: 
5101-5190 for stratum 1 (presence of hydroxyurea use); 6101 -6190 for stratum 2 (absence of 
hydroxyureause). There is no minimal or maximal number to which either stratum is 
expected to reach. A longer randomization list is chosen here as the sample size may be 
increased at re -evaluat ionwhen the stud y approaches the first interim analysis (Section 11.7).
The randomization number is only used to identify  which treatment the subjects have 
been 
randomized to receive. The Subject number assigned to a subject at screening remains the 
unique identifier for the subject throughout the study .  For information on subject numbering, 
please see ‘Subject numbering’ section in the SOM.
Subjects enrolled will use sequential subject numbering. There will be no replacement in this 
study , as a dropout rate of 20% is alread y taken into consideration in the sample size 
estimation.
The randomization scheme for subjects will be reviewed and approved by a m ember of the 
Randomization Office. The randomization numbers will be generated using the following 
procedure to ensure that treatment assignment is unbiased and concealed from subjects and 
investigator staff. A randomization list will be produced by or under the responsibility  of 
Novartis Drug Suppl y Management using a validated system that automates the random 
assignment of treatment arms to randomization numbers in the specified ratio.
Follow the details outlined in the Site Operations Manual regarding the process and timing of 
randomization of subjects.
6.4 Treatment blinding
This is a subject and investigator -blinded study . Subjects and investigators will remain 
blinded to study  treatment throughout the stud y, except where indicated below.
The identity  of the treatments will be concealed by the use of study  drugs that are all identical 
in packaging, labeling, schedule of administration, appearance, and odor.
Novartis Confidential Page 47
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Site sta ff
With the exception of any unblinded site staff identified below, all site staff (including study 
investigator and study  nurse) will be blinded to study treatment throughout the study :
The unblinded site pharmacist ordedicated unblinded site personnel will assign the treatment 
according to the randomization list. Unblinded site personnel will only be involved inthe 
treatment preparation for administration.
Unblinding a single subject at site for safet y reasons (necessary  for subject management) will 
occur via an emergency  system in place at the site (see Section 6.7 ).
Sponsor staff
The following unblinded sponsor roles are required for this study :
Unblinded sample anal yst(s) (PK blood)
The sample analysts will receive a copy of the randomization schedule (via request to the 
Randomization Office), to facilitate analy sis of the samples. The sample analy sts will provide 
the sample data to the study  team under blinded conditions unless otherwise allowed.
The study  statistician will be able to access the randomization list for interim analyses and is 
allowed to share unblinded information with the rest of the clinical team as appropriate for 
internal decision purposes, as outlined in Table 6-1. For example, unblinded summaries and 
unblinded individual data can be shared with the team for inter
im analy ses.
Study  programmers and other personnel involved in study  data analysis (e.g.,biomarker 
expert) are allowed to access treatment assignment information for the purpose of conducting 
interim anal yses.
The clinical trial team is allowed to share unblinded results with other sponsor staff 
(e.g. decision boards) as required for internal decision making on the study  or the project at 
the time of interim anal yses while the study is ongoing.
All unblinded personnel will otherwise keep randomization lists and data or information that 
could unblind other study team members confidential and se cure except as described above.
Novartis Confidential Page 48
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Following final database lock all roles may  be considered unblinded.
Table 6-1 Blinding levels
RoleTime or Event
Randomization 
list genera tedTreatment 
allocation & 
dosingSafety event 
(single subject 
unblinded)Interim Analysis 
& dose escalation
Subjects/Patients B B UI B
Site staff B B UI B
Pharmacist and unblinded site staff UI UI UI UI
Drug Supply and Randomization 
OfficeUI UI UI UI
Statistician/statistical 
programmer/data analystsB B UI UI
All other sponsor staff not identified 
aboveB B UI UI
B Remains blinded
UI Allowed to be unblinded at individual patient level
6.5 Treating the subject
ACZ885 will be administered to the subject at the study  site via subcutaneous injection , 
followed by a minimum, post-dose monitoring period of 15 minutes to monitor for evidence 
of hy persensitivity  reaction to the I MP (e.g., altered vital signs, rash, headache) .
See the Site Operations Manual for further details.
Sponsor qualified medical personnel will be readily  available to advise on trial related 
medical questions or problems.
6.6 Permitted dose adjustments and interruptions of study  treatment
Scheduled dosing of study  drug may be delay ed by up to 5 days if subjects present with 
conditions that require withholding of study  drug, e.g., evidence for active infection (treated 
or untreated) or acute abdominal pain. Outside of this 5 day window, the dose will be considered 
missed. These changes must be recorded on the Dosage Administration Record CRF .
6.7 Emergency  breaking of assigned treatment code
Emergency  unblinding must only be undertaken when it is essential to treat the subject safel y 
and efficaciously . Most often, study  treatment discontinuation and knowledge of the possible 
treatment assignments are sufficient to treat a study  subject who presents with an emergency  
condition. A complete set of emergency  code break cards will be provided to the investigator 
site(s) and a complete set will be available at Novartis. All code break cards must be retained 
until the end of the study  and returned to Novartis. They  must be stored in a secure place but 
be accessible to the investigator 24 hours per day in case of emergency . The investigator will 
receive a blinded code break card for each subject, with the details of study treatment covered 
by a removabl e, scratch -off cover. In an emergency , the scratch- off cover can be removed to 
determine the treatment. The scratch -off covers are not to be removed for any reason other 
than an emergency . When the investigator removes the scratch -off cover he/she must note the 
Novartis Confidential Page 49
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
date, time, and reason for removing it and retain this information with the case report form 
documentation. The unblinded treatment code must not be recorded on the CRF.
Theinvestigator must also immediately  inform the study  monitor that the code has been 
broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the code break cards at any time in case of emergency .   Th e investigator will 
need to provide: 
protocol number
study  drug na me (if available)
subject number.
In addition, the investigator must provide oral and written information to inform the subject 
how to contact his/her backup in cases of emergency  when he/she is unavailable to ensure that 
un-blinding can be performed at an y time.
An assessment will be done by the appropriate site personnel and sponsor after an emergency 
unblinding to assess whether or not study  treatment should be discontinued for a given subject 
and, if applicable, whether the subject can continue into the next trial phase.
6.8 Treatment exposure and compliance
Pharmacokinetic parameters (measures 
of treatment exposure) will be determined in all 
subjects treated with ACZ885, as detailed in Section 8.7
6.9 Recommended treatment of adverse events
There is no treatment that can reverse the activity  of ACZ885. Given that ACZ885 is an IgG1 
isoty pe monoclonal antibody , plasmapheresis may be of value in removing ACZ885 from the 
body . Potential adverse events should therefore be treated sy mpto maticall y at the discretion of 
the Investigator. Medication used to treat AEs must be recorded on the concomitant 
medications/significant non- drug therapies eCRF.
6.10 Rescue medication
In the context of this study , rescue medications are defined as those medic ations used acutel y 
to directl y manage medical signs or symptoms related to the subject’s underl ying sickle cell 
disease. Patients may receive hydration and analgesics for chronic or episodic pain with 
recording of analgesic type and dosing information in daily  diary.Patients are allowed to 
receive acute blood transfusions during the study ; such intervention must be captured in the 
CRF.
6.11 Concomitant treatment
Subjects will be maintained on their pre-existing stable medical regimen for treatment of 
preexist ing medical conditions, including sickle cell anemia. Common potential concomitant 
medications in this study  population are anticipated to include analgesics and stable 
hydroxyureatherapy , defined as an hydroxyurea dosing regimen that remains fixed except for 
Novartis Confidential Page 50
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
any adjustments according to hematologic parameters or other standard of care clinical 
monitoring.
All prescription medications, over-the-counter drugs and significant non-drug therapies 
(including physical therapy  and blood transfusions) administered or taken within the 
timeframe defined in the entry  criteria prior to the start of the study  and during the study must 
be recorded on the concomitant medications/significant non -drug therapies section of the CRF.
Medication entries should be specific to trade name, the single dose and unit, the frequenc y 
and route of administration, the start and discontinuation date and the reason for therapy .
7 Study  completion and discontinuation
7.1 Stud y completion and post -stud y treatment
Each subject will be required to complete the study  in its entirety  and thereafter no further 
study  treatment will be made available to them. The study  will complete when the last subject 
completes their Study  Completion visit, and any repeat assessments associated with this visit 
have been documented and followed -up appropriately  by the Investigator.
7.2 Discontinuation of study  treatment
Subjects may voluntaril y discontinue from the study  for any reason at any time. They  may be 
considered withdrawn if they  state an intention to withdraw, fail to return for visits, or become 
lost to follow -up for an y other reason.
Any patient who discontinues the study  early  will complete the EOS visit, about 8 weeks after 
the last dosing visit.
If a subject discontinuation occurs for any reason, the investigator must make every  effort to 
determine the primary  reason for a subject’s discontinuation from the study  and record this 
information on the CRF.
The investigator should discontinue study  treatment for a given subject or discontinue the 
subject from study  if, on balance, he/she believes that continuation would be detrimental to 
the subject’s well -being.
Study  treatment must be permanentl y discontinued under the following circumstances:
Subject withdraws consent
Pregnancy
Severe allergic reaction or anaph ylaxis following administration of the study  drug
Emergence of the following adverse events:
Serious infections combined with neutropenia CTC grades ≥1 (ANC <1.5 x 109/L)
Confirmed diagnosis of active TB
Onset of an y malignancy
Any of the following l aboratory  abnormalities:
Neutropenia CTCAE v4.03 Grades ≥3: neutrophils <1.0 x 109/L
Thrombocy topenia CTCAE v4.03 Grade 3: platelets <50.0 x 109/L
Novartis Confidential Page 51
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
Use of prohibited treatment as per Table 5 -1.
Any other p rotocol deviation that results in a significant risk to the patient’s safet y
The appropriate personnel from the site and Novartis will assess whether study  treatment 
should be discontinued for any subject whose treatment code has been 
broken inadvertentl y 
for an y reason.
Subjects who discontinue study  treatment should NOT automatically  be considered 
withdrawn from the study. 
For subjects who are lost to follow -up (i.e., those subjects whose status is unclear because 
they fail to appear for study  visits without stating an intention to withdraw), the investigator 
should show "due diligence" by documenting in the source documents steps taken to contact 
the subject, e.g., dates of telephone calls, registered letters, etc.
Subjects who are withdrawn from the study before Week 24 for reasons other than safet y or 
lack of efficacy  will be replaced on a case -by-case basis.
7.3 Withdrawal of informed consent
Subjects may  voluntarily  withdraw consent to participate in the study  for any  reason at any  time.
Withdrawal of con sent from the study  is defined as when a subject:
Does not want to participate in the study  anymore and
Does not want an y further visits or assessments and
Does not want an y further study  related contacts and
Does not allow anal ysis of already  obtained biologic material.
In this situation, the investigator must make every  effort (e.g.,telephone, e-mail, letter) to 
determine the primary  reason for the subject’s decision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact the subject are not allowed unless safety  findings require 
communicating or follow -up.
7.4 Lost to follow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator should show "due diligence" by 
documenting in the source documents steps taken to contact the subject, e.g.,dates of 
telephone calls, registered letters, etc. A subject cannot be formally  considered lost to 
follow -up until his/her scheduled end of stud y visit would have occurred.
Novartis Confidential Page 52
Amended Protocol Version v0 5 (Clean ) Protocol No. CACZ885X2206
7.5 Stud y Stopping rules
All subjects will undergo regular monitoring at scheduled visits for safety  and tolerabilit y, 
including adverse events, throughout the duration of the study . If significant risk to the study  
subjects is identified, the study  may be put on hold or terminated based on a full safety  review.
The study  can be terminated at any  time for any  reason by  Novartis. Should this be necessary , 
the patient should be seen as soon as possible and treated for a prematurely withdrawn patient. 
The investigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the patient's interests. The investigator 
will be responsible for informing the Institutional Review Board/Independent Ethics 
Committee of the early  termination of this trial. In addition, the study  will be paused if any of 
the following criteria are met, and no further dosing pending a full safety  review:
The observed proportion of patients having canakinumab -related serious adverse events 
such as infections, opportunistic infections, hypersensitivity , white blood cell (WBC) or 
platelet count decreases is 20% greater in canakinumab arm compared to placebo arm 
when enrollment is ≥10; when enrollment is below 10, at least 2 more patients with SAEs 
in the active arm than in the placebo arm.
A series of similar, new unexpected serious adverse events considered related to 
canakinumab in more than 3 individuals on active therap y.
7.6 Early study  termination by  the sponsor
The study  can be terminated by  Novartis at any  time for any  reason. This may  include reasons 
related to the benefit/ risk assessment of participating in the study, practical reasons 
(including slow enrollment), or for regulatory  or medical reasons. Should this be necessary , 
patients must be seen as soon as possible and treated as a prematurel y withdrawn patient. 
Theinvestigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the patient’s interests. Theinvestigator will 
be responsibl e for informing IRBs/IECs of the early  termination of the trial .
Novartis Confidential Page 53
Amended Protocol Version v05 ( Clean ) Protocol No. CACZ885X2206
8 Procedures and assessments
8.1 Assessment schedule
Study Phase Screening Randomized Treatment Open Label Treatment Post-Treatment Follow -Up
Visit Name Screening Baseline Randomized treatment Open label treatment EOS
Visit Numbers11 2 101 102 103 104 105 1062201 202 203 204 205 206 20723013
Study Day(s) -28 to - 14-14 to -1 129
±357
±385
±3113
±3141
±3169
±3197
±3225
±3253
±3281
±3309
±3337
±3393
±7
Time (post -dose) - - -1h40h - - - - - -1h 0h - - - - - - -
Informed consent X
Inclusion / Exclusion criteria S S
Concomitant therapies X X
Medical history/current medical 
conditionsX
Demography X
Alcohol Test and Drug Screen S S
Tuberculosis status S
Hepatitis screen S
HIV screen S
Pregnancy test X X X X X X X X X X X X X X X
Body height X
Body weight X X X X X X X X X X X X X X X
Physical examination S S S S S S S S S S S S S S S
Body temperature X X X X X X X X X X X X X X X X X
Blood pressure X X X X X X X X X X X X X X X
Pulse rate X X X X X X X X X X X X X X X
Study drug administration10X X X X X X X X X X X X
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 54
Amended Protocol Version v05 ( Clean ) Protocol No. CACZ885X2206
Study Phase Screening Randomized Treatment Open Label Treatment Post-Treatment Follow -Up
Visit Name Screening Baseline Randomized treatment Open label treatment EOS
Visit Numbers11 2 101 102 103 104 105 1062201 202 203 204 205 206 20723013
Study Day(s) -28 to - 14-14 to -1 129
±357
±385
±3113
±3141
±3169
±3197
±3225
±3253
±3281
±3309
±3337
±3393
±7
Time (post -dose) - - -1h40h - - - - - -1h 0h - - - - - - -
PK blood collection5X X X X X
Blood collection for IL -1β X X X X X X X
Immunogenicity X X X X X
Clinical Chemistry X X X X X X X X X9X9X9X9X9X9X9
Hematology X X X X X X X X X X X X X X X
Urinalysis X X X X X X X X X X X X X X
Oxygen Saturation X X X X
eDiary (Daily Pain VAS, Fatigue VAS, 
School/W ork absence)X8X8X X
Adverse events X X
Serious adverse events X X
Study completion information X
Commercially Confidential Information
Commercially Confidential InformationCommercially Confidential Information
Novartis Confidential Page 55
Amended Protocol Version v05 ( Clean ) Protocol No. CACZ885X2206
1Visit structure given for internal programming purpose only
2The end of each epoch is marked by the completion of the disposition CRF (X99) in the summary CRF section.
3For patients refusing the open label part or who stop the study early , the EOS will be conducted about 8 weeks after the last dosing.
4Baseline assessments can be performed on Day -1.
5The PK samples are taken pre -dose.
6.
7
8
9Haptoglobin is not measured in these samples. Haptoglobin will only be measured at screening, randomized treatment period and V201.
10ACZ885 will be administered to the subject at the study site via subcutaneous injection, followed by a minimum, post-dose monitoring period of 15 minutes to monitor 
for evidence of hypersensitivity reaction to the IMP (e.g., altered vital signs, rash, hea dache).
11
S Source data only, no tcaptured in the eCRF.
Commercially Confidential Information
Commercially Confidential Info rmation
Novartis Confidential Page 56
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
8.2 Informed consent procedures
Eligible subjects may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC -approved informed consent.
If incapable of doing so, in cases where the subject’s representative gives consent (if allowed 
according to local requirements), the subject must be informed about the study  to the extent 
possible given his/her understanding. If the subject is capable of doing so, he/she must 
indicate assent by personally  signing and dating the written informed consent document or a 
separate assent form.
Novartis will provide to investigators a propose d informed consent form that complies with 
the ICHE6 GCP guideline and regulatory  requirements and is considered appropriate for this 
study . The informed consent form will also include a section related to optional future 
research which will require a separate signature if the subject agrees to future research.  
Any changes to the proposed consent form suggested by  the investigator must be agreed to b y 
Novartis before submission to the I RB/IEC.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochure (IB). This information will be included in the subject 
informed consent and should be discussed with the subject during the study  as needed. 
Any new information regarding the safet y profile ofthe investigational drug that is identified 
between IB updates will be communicated as appropriate, for example, via an Investigator 
Notification or an Aggregate Safet y Finding. New information might require an update to the 
informed consent and then must be discussed with the subject.
Ensure subjects are informed of the contraception requirements outlined in the Section 4.2
(Exclusion criteria) and in Section 5.1 (Contraception requirements).
A copy  of the approved version of all consent f orms must be provided to the Novartis monitor 
after IRB/IEC approval.
8.3 Subject screening
Information on what data should be collected for screening failures is outlined in the Site 
Operations Manual.
Commercially Confidential Information
Novartis Confidential Page 57
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
8.4 Subject demographics/other baseline characteristics
Subject demographic and baseline characteristic data will be collected on all subjects.  
Relevant medical history/current medical conditions data will also be collected until signature 
of informed consent. Details are outlined in the Site Operations Manual .
Investigators have the discretion to record abnormal test findings on the medical history  CRF, 
if in their judgment, the test abnormality  occurred prior to the informed consent signature.
8.4.1 Alcohol Test and Drug Screen 
All subjects will be screened for substances of abuse. See the Site Operations Manual for 
details.
8.4.2 Tuberculosis status
Determination of TB status will be required before administration of study  treatment and 
should be performed as defined by local guidelines. For those patients in whom thepresence 
of TB infection is established, then the TB must be first adequately  treated and definitive cure 
demonstrated. 
Any significant findings will be recorded in the "Relevant medical history /Current medical 
conditions" section of the eCRF. 
8.4.3 HIV scree n
Evaluation for HIV seropositivity  will be performed, and, if positive, confirmation by a 
second technique available at the laboratory  site, e.g., Western blot .
Appropriate counseling will be made available by the Investigator in the event of a positive 
finding. Notification of state and local authorities, as required by law, will be the 
responsibility  of the Investigator .
Results will be available as source data and will not be re corded within the CRF.
8.4.4 Hepatitis screen
All subjects will be screened for He patitis B and C. See the Site Operations Manual for details.
8.5 Efficacy  / Pharmacody namics
Pharmacod ynamic assessments are specified below, with the methods for assessment and 
recording specified in the Study  Operations Manual. Assessments will be performed/ samples 
collected at the timepoint(s) defined in the Assessment schedule .
In order to better define the PD profile, the timing of the sample collection may be altered 
based on emergent data. The number of samples/blood draws and total blood volume 
collected will not exceed those stated in the protocol.
Novartis Confidential Page 58
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
8.5.1 Clinical Outcome A ssessments (COA s)
8.5.1.2 eDiary
Pain diaries are commonly  used to assess pain symptoms and response to treatm ent in 
children and adolescents with recurrent and chronic pain, with a recommended assessment 
time frame of at least 3 months ( McGrath et al 2008). In SCA patients, daily  diaries have been 
shown a more sensitive means of capt uring reported pain frequency  than through retrospective 
interviews (Porter et al1998 ). Furthermore, electronic diaries have been shown in adolescents 
to have additional advantages over the paper format of accuracy  as well ascompliance in 
recording patient -reported outcomes (McGrath et
al2008 ). In this study , we will use e -diaries 
to record the following 5 daily  outcomes:
a.Pain intensity. Most pain diaries use a simple visual analog scale (VAS) to record severity .
Children with SCA have been shown in numerous studies to reliably  self-report pain that is
specificall y attributable to sickle cell vaso -occlusion ( Shapiro et al 1995; Dampier et al 2002 a;
Dampier et 
al 2004). In this study , pediatric and young adult patients will rate their daily
sickle cell-
associated pain intensity  once each dayin the evening using an 11-point numerical
rating scale from 0 to 10 with higher ratings assoc iated with more intense pain (0= no pain,
10 = worst pain). Numerical rating scales are a valid and reliable assessment tool and have
been recommended for asses sment of pain intensity  for both acute (Pagé et
al2012 ) and
chronic pain (Ruskin et al 2014) in adolescents. In addition, patients noting pain above the
level of 0 will be prompted to provide theapproximate duration of their pain (<2hours, 2
-6
hours, >6 hours).
b. Fatigue. Similar to pain intensity , a single item measure can be used for accuratel y
capturing fatigue data in daily  diaries, with convergent validit y to validated, multiple -item
measur es of fatigue (Van Hooff et al2007). In this study  patients will be instructed to answer
the question, “how fatigued do you currentl y feel?” using an 11-point numerical rating scale
with higher rating associated with more severe fatigue (0 = not at all, 10 = extremely ).
c.Interference with daily tasks. Study  subjects will rate the 
extent that their sickle cell pain
kept them from daily activities, such as seeing friends, doing chores, playing, sports, etc.,
using an 11 -point numerical rating scale (0 = not at all, 10 = completel y).
d.Medication use. Study  subjects who respond, ‘yes’ for medication use are instructed to
record the category  of pain medication (acetaminophen/paracetamol, NSAID/COX -2 inhibitor,
Narcotic, Other ).
e.Absence from school and/or work. Study  subjects will answer whether they have missed
any school or job time. (Yes, missed due to SCA; Yes, missed due to other reasons; No, did
not miss; No, but I am not a student/have no job; No school/work today (weekend, break,
holiday , etc.).
Commercially Confidential Information
Novartis Confidential Page 59
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
8.6 Safet y
Safet y assessments are specified below; methods for assessment and recording are specified in 
the Site Operations Manual, with the Assessment Schedule (Section 8.1) detailing when each 
assessment is to be performed.
8.6.1 Blood pressure
Blood pressure (BP) will be measured
8.6.2 Body height
Height will be measured.
8.6.3 Body temperature
Body temperature will be measured.
8.6.4 Body weight
Body weight will be measured
Body mass index (BMI) w ill be calculated as (body  weight (kg) / [height (m)]2)
8.6.5 Clinical Chemistry
Sodium, potassium, magnesium, protein, creatinine, BUN/urea, uric acid, chloride, albumin, 
calcium, alkaline phosphatase, total bilirubin, direct and indirect bilirubin, bicarbonate /HCO 3, 
LDH, γ
-GTAST, ALT, amylase, lipase, CK, glucose, total cholesterol, triglycerides, LDL, 
HDL, hs-CRP, haptoglobin. 
8.6.6 Hematology
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differentials and 
reticulocy te count will be mea sured.
8.6.7 Immunogenicity
To assess potential immunogenicit y, serum samples for detection of anti-canakinumab 
antibodies will be collected during the study  (see Assessment Schedule ).
The instructions outlined inthe Central Laboratory  Manual regarding sample collection, 
numbering, processing, and shipment will be followed.
In the case of an anaphy lactic reaction occurring after injection, a sample will be taken at the 
time of the event and 8 weeks later. An immun ogenicity  positive subject at the end of the 
study  will be followed up for three months.
Immunogenicity  analytical method
An ELISA -based method will be used for the detection of potential anti-canakinumab 
antibody  formation. The detailed method description to assess immunogenicity  will be 
described alongside the bioanaly tical raw data of the study  in the respective Bioanaly tical 
Data Report (BDR).
Novartis Confidential Page 60
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
8.6.8 Pulse rate
Pulse rate will be measured
8.6.9 Urinaly sis
Dipstick measurements for specific gravit y, albumin, protein, glucose and blood will be 
performed. Microscop y, WBC, RBC and sediments will also be assessed in case of an 
abnormal dipstick test.
8.6.10 Pregnancy  test
All pre-menopausal women who are not surgically  sterile will have pregnancy  testing.  
Seethe Assessment Schedule Section 8.1, for timing of the protocol required pregnancy 
testing; additional pregnancy  testing may be performed to meet local requirements*.  
Apositive urine pregnancy  test requires im
mediate interruption of study  treatment until serum 
β-hCG is performed and found to be negative.
*If additional pregnancy  testing is needed per local requirements, those additional results will
be kept as source documentation only .
8.6.11 Physical examination
SeeSite Operations Manual for details.
8.7 Pharmacokinetics
PK samples will be collected at the time points defined in the Assessment schedule, 
Section 8.1. The instructions outlined in the Site Operations Manual regarding sample 
collection, 
numbering, processing and shipment will be followed. See Section 8.9regarding 
the potential use of residual samples.
In order to better define the PK profile, the timing of the PK sample collecti on may  be altered 
based on emergent data. The number of samples/blood draws and total blood volume 
collected will not exceed those stated in the protocol.
Pharmacokinetic (PK) samples will be obtained and evaluated in all subjects at all dose levels.
For standard pharmacokinetic abbreviations and definitions see the list provided at the 
beginning of this protocol.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 61
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
zero in summary  statistics. The geometric mean will not be reported if the dataset include s 
zero values.
8.8 Other assessments
Commercially Confidential Information
Novartis Confidential Page 62
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
Commercially Confidential Information
Novartis Confidential Page 63
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
8.9 Use of residual biological samples
Residual blood and urine samples may be used for another protocol specified endpoi nt.
9 Safety  monitoring
9.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign including abnormal laboratory  findings, symptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study  until the end of study  visit. Therefore, an AE may or may not be temporally  or causall y 
associated with the use of a medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the study  treatment are also 
considered an adverse event irrespective if a clinical event has occurred. See Section 9.5 for 
an overview of the reporting requirements.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 64
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
The occurrence of adverse events must be sought by non-directive questioning of the subject 
at each visit during the study . Adverse events also may  be detected when they  are volunteered 
by the subject during or between visits or through physical examination finding, laboratory  
test finding, or other assessments.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms,
they are considered clinically
 significant,
they require therapy .
Clinically  significant abnormal laboratory  values or test results should be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typical in patients with 
underl ying disease. Investigators have the responsibility  for managing the safet y of individual 
subject and identify ing adverse events. Alert ranges for liver and kidney  related events are 
included in Appendix 1 and Appendix 2 , respectively.
Pre-existing medical conditions/diseases (i.e., Medical History (ies)) are considered AEs if 
they worsen after providing written informed consent.
Adverse events must be recorded on the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, and accompanied by  the following information:
1.the severit y grade
mild: usually  transient in nature and generally  not interfering with nor mal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
2.its relationship to study  treatment
3.its duration (start and end dates) or if the event is ongoing an outcome of not
recovered/not resolved must be reported.
4.whether it constitutes an SAE (see Section 9.2 for definition of SAE) and which
seriousness criteria have been met
5. Action taken regarding investigational treatment.
All adverse events must be treated appropriatel y. Treatment may include one or more of the 
following:
no action taken (e.g. further observation only )
investigational treatment dosage increased/reduced
investigational treatment interrupted/withdrawn
concomitant medication or non- drug therap y given
hospitalization/prolonged hospitalization (see Section 9.2 for definition of SAE)
6.its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving,
recovered/resolved with sequelae; fatal; or unknown).
Novartis Confidential Page 65
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochure (IB).  Once an adverse event is detected, it must be 
followed until its resolution or until it is judged to be permanen t, and assessment should be 
made at each visit (or more frequentl y, if necessary ) of any changes in severity , the suspected 
relationship to the investigational drug, the interventions required to treat it, and the outcome.
The investigator must also instru ct each subject to report any new adverse event (beyond the 
protocol observation period) that the subject, or the subject’s personal physician, believes 
might reasonabl y be related to study  treatment. This information must be recorded in the 
investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be 
reported to Novartis.
9.2 Serious adverse event reporting
9.2.1 Definition of SA E
An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the 
following criteria:
is fatal or life -threatening
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless
hospitalization is for:
routine treatment or monitoring of the studied indication, not associated with any
deterioration in condition
elective or pre -planned treatment for a pre -existing condition (that is unrelated to the
indication under study  and has not worsened since the start of study  drug
treatment on an emergency  outpatient basis for an event not fulfilling any  of the
definitions of an SAE given above and not re sulting in hospital admission
social reasons and respite care in the absence of any  deterioration in the subject’s
general condition
is medically  significant, e.g. ,defined as an event that jeopardizes the subject or may
require medical or surgical interve ntion.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of an SAE refers to a reaction in which the subject was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically  might 
have caused death if it were more severe (see Annex I V, ICH -E2D Guideline).
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospitalization but might jeopardize the 
subject or might require intervention to prevent one of the other outcomes listed above. 
Example s of such events are intensive treatment in an emergency  room or at home for allergic 
Novartis Confidential Page 66
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization or 
development of dependency or abuse (see Annex IV, ICH-E2D Guideline).
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All AEs (serious and non-serious) are captured on the CRF; SAEs also require individual 
reporting to Novartis Drug Safet y & Epidemiology (DS&E) as p er Section 9.2.2 .
9.2.2 SAE reporting
To ensure subject safet y, every  SAE, regardless of causalit y, occurring after the subject has 
provided informed consent and until 30 days after the last study  visit must be reported to 
Novart is within 24 hours of learning of its occurrence as described below. Any SAEs 
experienced after this period should only be reported to Novartis if the investigator suspects a 
causal relationship to study  treatment.
Note: SAEs reported by subjects deemed tobe screen failures must be reported to Novartis as 
outlined here with appropriate information also captured in the CRFs as specified in the Site 
Operations Manual.
All follow -up information for the SAE including information on complications, progression o f 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up information. An SAE occurring at 
a different time interval or otherwise considered completely  unrelat ed to a previously  reported 
one must be reported separatel y as a new event.
Follow -up information provided must describe whether the event has resolved or continues, if 
and how it was treated, whether the blind was broken or not (if applicable) and whethe r the 
subject continued or withdrew from study  participation. Each re-occurrence, complication, or 
progression of the original event must be reported as a follow -up to that event regardless of 
when it occurs.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the study  treatment a Drug Safet y and 
Epidemiology  Department associate may urgently  require further information from the 
investigator for Health Authority  reporting . Novartis may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same study  
treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(SUSARs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with EU Guidance 2011/C 172/01 or as per national regulatory 
requirements in participating countries.
Follow the detailed instructions outlined in the Site Operations Manual regarding the 
submission process for reporting SAEs to Novartis.   Note:  SAEs must be reported to 
Novartis within 24 hours of the investigator learning of its occurrence/receiving follow -up 
information.
Novartis Confidential Page 67
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
9.3 Liver safety  monitoring
To ensure subject safety  and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
Please refer to Table 15 -1-Appendix 1 for complete definitions of liver events.
Follow -up of liver events
Every  liver event defined in Table 15 -
1-Appendix 1 should be followed up by  the investigator 
or designated personnel at the trial site, as summarized below. Additional details 
on actions 
required in case of liver events are outlined in Table 15 -2-Appendi x 1. 
Repeating liver chemistry tests (ALT, AST, TBL, PT/I
NR, ALP and γGT) to confirm
elevation within 48- 72 hours.
These liver chemistry  repeats should alway s be performed using the central laboratory ,
with the results provided via the standard electronic transfer.  If results will not be
available from the central laboratory  within 24 hours, then the repeats can also be
performed at a local laboratory  to monitor the safety  of the subject. If a liver event is
subsequently  reported, any  local liver chemistry  tests previously  conducted that are
associated with this event should have results reported on the unsch eduled loc al laboratory  CRF .
If the initial elevation is confirmed, close observation of the subject will be initiated,
including consideration of treatment interruption if deemed appropriate.
Discontinuation of the investigational drug (refer to Section 7.2 (Discontinuation of study
treatment), if appropriate
Hospitalization of the subject if appropriate
Causality  assessment of the liver event
Thorough follow -up of the liver event should include:
Repeating liver chemistry tests two o r three times weekl y. Testing should include
ALT, AST, AL P, PT/INR, and γ-GT. If total bilirubin is elevated > 2 x ULN,
fractionation into direct and indirect bilirubin is required. To rule out muscular origin
of transaminase elevations, CPK should be measured along with liver chemistry  tests.
Frequency  of retesting can decrease to once a week or less if abnormalities stabilize
or the study  drug has been discontinued and the subject is asy mptomatic. Retesting
should be continued up to resolution.
Obtaining a more detailed history  of symptoms and prior or concurrent diseases.
Obtaining a history  of concomitant drug use (including nonprescription medications
and herbal and dietary  supplement preparations), alcohol use, recreational drug use,
and special diets
.
Exclusion of underly ing liver disease, as specified in Table 15-3 .
Imaging such as abdominal US, CT or MRI , as appropriate
Obtaining a history  of exposure to environmental chemical agents.
Considering gastroenterology  or hep atology  consultations.
Novartis Confidential Page 68
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
All follow -up information, and the procedures performed must be recorded as appropriate in 
the CRF.
9.4 Renal safety  monitoring
Every  renal laboratory  trigger or renal event must be followed up by the investigator or 
designated personnel at the trial site. Recommended follow -up assessments are listed in 
Section 16- Appendix 2 .
9.5 Reporting Medication errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, 
administration or 
monitoring of a medicine while under the control of a healthcare professional, patient/subject 
or consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropria tely 
used not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by  harmful ph ysical or psy chological effects.
All study  treatment errors and uses outside of what is foreseen in the protocol will be 
collected in the dose administration record (DAR) CRF.  Study  treatment errors are only  to be 
reported to Novartis Drug Safet y and Epidemiology  department if the treatment error is 
associated with an SAE.
All instances of misuse or abuse must be documented in the adverse event (AE) CRF 
irrespective of the misuse/abuse being associated with an AE/SAE. In addition, all instances 
of misuse or abuse must be reported to Novartis Drug Safet y and Epidemiology . As such, 
instances of misuse or abuse are also to be reported using the SAE form/CRF. Table 9-1
summarizes the reporting requirements.
Table 9
-1 Summary  of reporting requirements for medication errors
Treatment error type Document in Dose 
Administration (DA R) CRF Document in A E 
CRFComplete SA E 
form/CRF 
Unintentional study 
treatment errorYes Only if associated 
with an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with an 
SAE
For more information on AE and SAE definition and reporting requiremen ts, 
please seeSection 9.1 and Section 9.2, respectively.
Novartis Confidential Page 69
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
9.6 Pregnancy  reporting
To ensure patient safety, each pregnancy  in a subject on study  drug must be reported to 
Novartis within 24 hours of learning of its occurrence. The pregnancy  should be followed up 
to determine outcome, including spontaneous or voluntary  termination, details of the birth, 
and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications. The study  drug must be discontinued, though the subject may stay in 
the study , if she wishes to do so. All assessments that are considered as a risk durin g 
pregnancy  must not be performed. The subject may  continue all other protocol assessments.
Pregnancy  must be recorded on a Pharmacovigilance Pregnancy  Form and reported by the 
investi gator to the local Novartis Drug Safet y and Epidemiology  Department. Pregnanc y 
follow -up should be recorded on the same form and should include an assessment of the 
possible relationship to the study treatments.
Any SAE experienced during pregnancy  and unr elated to the pregnancy  must be reported on 
an SAE Report Form.
The study  drug must be discontinued, though the subject may stay in the study , if she wishes 
to do so. All assessments that are considered as a risk during pregnancy  must not be 
performed. The subject may  continue all other protocol assessments.
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained fr om the mother. 
9.7 Early phase safety  monitoring
The Investigator will monitor adverse events in an ongoing manner and inform the Sponsor of 
any clinically  relevant observations. Any required safet y reviews will be made jointly 
between medicall y qualified personnel representing the Sponsor and Investigator. 
Such evaluations may occur verball y, but the outcome and key discussion points will be 
summarized in writing (e-mail) and made available to both Sponsor and all Investigator(s). 
Criteria pertaining to stopping the study /treatment or adapting the study  design are presented 
above.
When two or more clinical site(s) are participating in the clinical study, the Sponsor will 
advise the Investigator(s) at all sites in writing (e-mail) (and by telephone if possible) of any 
new, clinically  relevant safet y information reported from another site during the conduct of 
the study  in a timel y manner.
10 Data revie w and database management
10.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and CRFs with the invest igators and their staff. 
During the study  Novartis employ s several methods of ensuring protocol and GCP 
compliance and the quality /integrit y of the sites’ data. Themonitor will visit the site to check 
the completeness of subject records, the accuracy  of entries on the CRFs, the adherence to the 
Novartis Confidential Page 70
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
protocol and to Good Clinical Practice, the progress of enrollment, and ensure that study  drug 
is being stored, dispensed, and accounted for according to specifications. Key  study  personnel 
must be available to assist the monitor during these visits.
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
subject's file. The investigator must also keep the original informed consent form signed by 
the subject (a signed copy  is given to the subject).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. Novartis monitoring standards require full verification 
for the presence of informed consent, adherence to the eligibility  criteria, documentation of 
SAEs, and the recording of data that will be used for all primary  and safet y variables. 
Additional checks of the consistency  of the source data with the CRFs are performed 
according to the study -
specific monitoring plan. No information in source documents about 
the identity  of the subjects will be disclosed.
10.2 Data collection
Designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms using fully validated software that conforms to 21 CFR Part 11 
requirements. Designated investigator site staff will not be given access to the EDC system 
until they  have been trai ned. Automatic validation programs check for data discrepancies and, 
by generating appropriate error messages, allow the data to be confirmed or corrected before 
transfer of the data to the Contract Research Organization (CRO) working on behalf of 
Novartis . The Investigator must certify  that the data entered into the Electronic Case Report 
Forms are complete and accurate. After database lock, the investigator will receive copies of 
the subject data for archiving at the investigational site.
Data not requiri ng a separate written record will be defined in the Site Operations Manual and 
Assessment schedule and can be recorded directly  on the CRFs. All other data captured for 
this study  will have an external origi nating source (either written or electronic) with the CRF 
not being considered as source.
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
10.3 Database management and quality  control
Cmed review the data entered into the CRFs by investigational staff for completeness and 
accuracy  and instruct the site personnel to make an y required corrections or additions. 
Queries are sent to the investigational site using an electronic data query . Designated 
investigator site staff is required to respond to the query  and confirm or correct the data. If the 
electronic query  system is not used, a paper Data Query  Form will be faxed to the site. 
Sitepersonnel will complete and sign the faxed copy  and fax it back to Cmed who will make 
the correction to the database. The signed copy  of the Data Query  Form is kept at the 
investigator site.
Novartis Confidential Page 71
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employ s the Anatomical Therapeutic Chemical classification system. 
Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Laboratory  samples will be processed centrall y andthe results will be sent electronically  to 
Novartis (or a designated CRO).
Diary  data will be entered into an electronic diary by the subject. The system will be supplied 
by a vendor(s), who will also manage the database. The database will be sent electronically  to 
Novartis (or a designated CRO).
At the conclusion of the study , the occurrence of any emergency  code breaks will be 
determined after return of all code break reports and unused drug supplies to Novartis.
The occurrence of any protocol deviations will be determined. After these actions have been 
completed and the database has been declared to be complete and accurate, it will be locked 
and the treatment codes will be unblinded and made available for data analy sis. Any changes 
to the database after that time can only be made by joint written agreement between the 
COAR Analy tics NIBR Franchise Head and the relevant NIBR TA Head.
10.4 Data Monitoring Committee
Not required.
10.5 Adjudication Committee
Infection A djudication Committee
An external, independent Infection Adjudication Committee (IAC) has been formed on a 
program level and will review pertinent data from this trial.
The mission of the canakinumab IAC is to independently  and blinding review, evaluate and 
categorize new reports of pre-defined infections as they become available during the conduct 
of this trial.
The members, detailed mission and procedures of the IAC are detailed in the IAC charter 
which is available upon request.
Commercially Confidential Information
Novartis Confidential Page 72
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
Malignancy  Adjudication Committee
An external, independent Malignancy  Adjudication Committee (MAC) has been formed on a 
program level and will review pertinent data from this trial.
The mission of the MAC is to independentl y and blinding review, evaluate and categorize 
reports of malignancy events across all potential indications and therapeutic areas in the 
canakinumab development program.
The members, detailed mission and procedures of the MAC are detailed in the MAC charter 
which is available upon request.
11 Data analy sis
The analysis will be conducted on all subject data at the time the trial ends. Any data analysis 
carried out independently  by the investigator should be submitted to Novartis before 
publication or presentation. The key safety and efficacy  endpoints will also be reported for 
pediatric (<18 years old) and adult (>=18 years old) cohorts separatel y per internal SOP 
requirement. Details will be explained in statistical anal ysis plan document. 
11.1 Analysis sets
For all anal ysis sets, subjects will be anal yzed accord ing to the stud y treatment(s) received.
The safety  anal ysis set will include all subjects that received any  study  drug.
The PK analysis set will include all subjects with at least one available valid (i.e., not flagged 
for exclusion) PK concentration measu rement, who received any study drug and with no 
protocol deviations that impact on PK data.
The primary  PD analysis set will include all subjects with available PD data and no protocol 
deviations with relevant impact on PD data. For example, patients missi ng more than two 
consecutive doses or more during the blinded treatment period will be excluded from the 
primary  PD analysis set. The secondary  PD analy sis set will include all subjects with 
available PD data.
11.2 Subject demographics and other baseline charac teristics
All data for background and demographic variables will be listed by treatment group and 
subject. Summary  statistics will be provided by treatment group. Subject demographics will 
include age, gender, race, ethnicit y, country , height, weight and BMI. Baseline disease 
characteristics include but are not limited to: baseline average daily pain VAS, baseline 
hs-CRP, the number of VOPE in the previous y ear.
Relevant medical history, current medical conditions, results of laboratory screens, drug tests 
and an y other relevant information will be listed by treatment group and subject.
11.3 Treatments
Data for study  drug administration (rescue medication) and concomitant therapies will be 
listed by  treatment group and subject.
Novartis Confidential Page 73
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
11.4 Analysis of the primary  variable(s)
The primary  aim of this study  is to assess if inhibition of IL-1β by canakinumab will reduce 
average daily pain in pediatric and young adult patients with sickle cell anemia. 
Statistical analy sis plan for this primary  endpoint will be described below in details.
11.4.1 Variable(s)
A numerical pain VAS score between 0 and 10 will be recorded by each patient once daily. 
An average daily  pain VAS will be calculated for every  4  w eeks and the reduction from 
baseline of the 4 -week average dail y pain VAS will be the primary  variable for this study .
11.4.2 Statistical model, hypothesis, and method of analy sis
The post-baseline average daily  pain VAS will be calculated for each dose from the start of 
the dose till the day  before the next dose, i.e. in an averagely  4-week interval (e.g., Week 0 -4, 
Week 4-8, etc. depending on the actual dosing days). The baseline average pain VAS will be 
calculated as the average of daily  pain scores from screening up to pre -dosing over a period of 
at least 7 days. Reduction from baseline in the average daily pain VAS, i.e., baseline minus 
post-baseline, will be analy zed using a Bayesian model for repeated measures using Proc 
MCMC in SAS (Chen 2011). Themodel will include baseline average daily  pain score asa 
continuous covariate; treatment group, time and hydroxyureause history (Yes/No) as fixed 
factors. Interactions of time by treatment group and time by baseline covariates will also be 
included in the model. Non-informative priors will beused for the fixed effects and weakly 
informative prior ,for the covariance . Unstructured covariance structure will be used and other 
covariance structure will be investigated if there is convergence problem . Interaction of 
hydroxyureause and treatment group will be explored via visualizations; if substantial 
interaction is suspected it will be further explored by including this interaction term in the 
whole model.
A comparison of canakinumab 300 mg s.c. versus placebo for the period o f Week 8 -12 is of primar y 
interest. Data up to Week 12 will be included in the primary  model. Bayesian posterior probabilities
will be used to assess the following PoC criteria as a guidance for decision making
(Fischetal2015 )
:
Prob (the reduction of average pain score over the period of Week 8-12 in canakinumab is 
greater than Placebo) > 90%, and
Prob (the reduction of average pain score over the period of Week 8-12 in canakinumab is 
greater than Placebo b y 1) > 50%.
The target difference of 1 is chosen based on the literature search on the Minimally  Clinical 
Important Difference (MCI D) in pain studies (see Section 11.7).
Data up to Week 24 will also be analy zed with the same model 
specifications when there are 
at least about 50% completers at Week 24 and also upon the study  completion. Pain data in 
the open label period when available will also be summarized, visualized and explored in 
Commercially Confidential Information
Novartis Confidential Page 74
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
appropriate statistical models, to evaluate the maintenance of the efficacy  in patients 
randomized to canakinumab group and/or improvements in patients randomized in placebo 
group. 
11.4.3 Handling of missing values/censoring/discontinuations
For the primary  analysis, data for those patients who have received acute blood transfusion(s) 
during the study  will be truncated up to the first occurrence of acute blood transfusion, i.e. 
data since the first blood transfusion will be considered as missing. Assuming the occurrence 
of acute blood transfusion being random to this patient population, such missing data are 
considered Missing at Random (MAR). As a supportive analysis, the complete data will be 
analyzed as if the patients did not receive any  blood tr ansfusion ( Section 11.4.5 ). 
Early discontinuations not due to lack of efficacy  support the assumption of Missing at 
Random (MAR). In such scenarios MMRM remains valid. In the primary  analysis for the 
blind ed treatment period, if there were any patients who discontinued early  due to lack of 
efficacy , LOCF (last observation carried forward) approach will be applied as a sensitivit y 
analysis to deal with such missing data.
11.4.4 Sensitivity analy ses
An Intention -To-Treat (ITT) analysis will also be explored as a sensitivity  analysis to include 
all patients who received at least one study  drug treatment (the second PD analysis set), 
ifthere are patients excluded in the primary  PD analysis set, for example those who have 
missed two consecutive dosing or more.
11.4.5 Supportive analy ses
As a supportive analysis, all collected data inthe double -
blinded period will be analy zed in 
the same way as described inSection 11.4.2, without truncation of data due to acute blood 
transfusions .This is to explore the possible impact of such rescue therapy  to the treatment 
effect.
Non-convergence of the primary  analy sis may  occur when there is a great amount of truncated 
data due to acute blood transfusion. In that scenario the evaluation of efficacy  may focus on 
the anal ysis of the 
rate of acute blood transfusion ( Section 11.5.4). 
11.5 Analysis of secondary  variable(s)
For the double -blinde d period, the main analy sis on secondary  efficacy  data, including 
inflammation and hemoly sis biomarkers, absence from school/work will also be based on 
truncated data up tothe time of the first acute blood transfusion where applicable. Complete 
data will also be summarized and visualized.
11.5.1 Efficacy  / Pharmacodynamics
To determine the duration of effects of canakinumab versus placebo on daily  pain, the average 
daily  pain VAS data after Week 12 will be analy zed, as explained in Section
11.4.2 . The dail y 
pain data will also be explored using visualizations.
Novartis Confidential Page 75
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
11.5.2 Inflammation and hemoly sis biomarkers at Week 12
The inflammation biomarkers, including hs-CRP, WBC count, absolute count of blood 
neutrophils and absolute count of blood monocy tes, will be summarized and visualized by 
treatment group and visit/time. For each of the inflammation biomarkers, change from 
baseline taken from log transformed values will be analyzed using an MMRM with the log 
baseline value as continuous covariate, treatment group, time, hydroxy urea use history 
(Yes/No) and race as factors. Unstructured covariance structure will be used.
The hemol ysis biomarkers, including hemoglobin concentration, reticulocy te count, 
haptoglobin, lactate dehy drogenase, total bilirubin , direct and indirect bilirubin and oxygen 
percent saturation (SaO2), will also be summarized and visualized by treatment group and 
visit/time. The same MMRM approach as for inflammation biomarkers will also be applied 
for each individual hemoly sis biomarker with log transformation.
For each of the biomarkers, the difference between canakin umab and placebo groups at 
Week 12 will be presented in terms of ratio of geometric mean because of the log 
transformation.
11.5.3 Absence from school/w ork
The number of SCA - related days absent from school or work will be derived from eDairy 
records. The data will be summarized and visualized by treatment group and visit/time. 
Anegative binomial Generalized Linear Model (GLM) will be fitted for the total number of 
SCA -related days absent from school/work up to Week 24 visit, with treatment group as the 
factor. The difference between canakinumab and placebo groups will be estimated.
11.5.4 Incidence of acute blood transfusion
The occurrence of acute blood transfusions will be summarized as the proportion of patients 
who receive at least one acute blood transfusion andthe event rate of acute blood transfusion s
per patient during double -blinded period and open -label period separatel y. 
The proportion of patients who receive at lea st one acute blood transfusion during the double -
blinded period will be analy zed in a binomial Bayesian model with non-informative prior for 
both groups (neutral prior Beta(1/3, 1/3), (Kerman 2011) and the posterior probability  of the 
difference of the two proportions ( placebo –ACZ885) will be presented. 
If the data allows ,the recurrent event analysis (at least one patient receiving more than one 
acute blood transfusion), t he time to recurrent incidence of acute blood transfusion
sduring the 
double -blinded period will be analy zed viathe Anders en-Gill model (Andersen & Gill 1982) , 
with treatment and hydroxyureause as independent variable s and time to last blood 
transfusion before stud y treatment (if available) as a continuous covariate. 
The incidence of acute blood transfusions will also be included in the visualizations of all 
efficacy  endpoints where applicable.
Novartis Confidential Page 76
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
11.5.5 Safety
Vital signs
All vital signs data will be listed by treatment group, subject and visit/time ,and where ranges 
are available ,abnormalities (and relevant orthostatic changes) will be flagged. Summary 
statistics will be provided by  treatment and visit/time.
Clinical laboratory  evaluations
All laboratory  data 
 will be listed by treatment group, subject, and visit/time ,and where normal 
ranges are available ,abnormalities will be flagged. Summary  statistics will be provided by 
treatment and visit/time.
Adverse events
All information obtained on adverse events will be display ed by treatment group and subject.
The number and percentage of subjects with adverse events will be tabulated by body system 
and preferred term with a breakdown by treatment. A subject with multiple adverse events 
within a body  system is only  counted once towards the total of this body  system.
The proportion of patients receiving any rescue medication/therap y post baseline will be 
summarized by  group and study period. 
Immunogenicity
All immunogenicity  results will be listed by  treatment group, subject and visit/time.
11.5.6 Pharmacokinetics
Canakinumab plasma concentration data will be listed by treatment, subject, and 
visit/sampling time point. Descriptive summary  statistics will be provided by treatment and 
visit/sampling time point, including the frequency (n, %) of concentrations below the LLOQ 
(lower limit of quantification) which will be reported as zero.
Summary  statistics will include mean (arithmetic and geometric), SD, CV (arithmetic and 
geometric), median, minimum and maximum . The impact of acute blood transfusions on PK 
data may  be explored.
11.5.7 Pharmacokinetic / pharmacodynamic interactions
Not applicable.
11.5.8 Other assessments
Not applicable.
Commercially Confidential Information
Novartis Confidential Page 77
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
11.6 Analysis of exploratory  variables
Commercially Confidential Information
Novartis Confidential Page 78
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
Commercially Confidential Information
Novartis Confidential Page 79
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
11.7 Sample size calculation
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 80
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
11.8 Power for analy sis of key secondary  variables
Not applicable.
11.9 Interim analy ses
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 81
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
12 Ethical considerations
12.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in 
accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations (including European Directive 2001/20/EC , US Code of Federal 
Regulations Title 21, and Japanese Ministry  of Health, Labor, and Welfare ), and with the 
ethical principles laid down in the Declaration of Helsinki.
12.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approva l/favorable opinion 
from the Institutional Review Board/Independent Ethics Committee (IRB/IEC) for the trial 
protocol, written informed consent form, consent form updates, subject recruitment 
procedures (e.g., advertisements) and any  other written informat
ion to be provided to subjects. 
Prior to study  start, the investigator is required to sign a protocol signature page confirming 
his/her agreement to conduct the study  in accordance with these documents and all of the 
instructions and procedures found in this protocol and to give access to all relevant data and 
records to Novartis monitors, auditors, Novartis Quality  Assurance representatives, designated 
agents of Novartis, IRBs/IECs, and regulatory  authorities as required. If an inspection of the 
clinical site is requested by a regulatory  authority , the investigator must inform Novartis 
immediately  that this request has been made.
For multi- center trials, a Coordinating Investigator will be selected by Novartis around the 
time of Last Patient Last Visit to b e a reviewer and signatory for the clinical study report. 
12.3 Publication of study  protocol and results
The key design elements of this protocol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. In addition, upon study  completion and finalization of the study  report 
the results of this trial will be either submitted for publication and/or posted in a publicl y 
accessible database of clinical trial results.
13 Protocol adherence
This protocol defines the study  objectives, the study  procedures and the data to be collected 
on study  participants. Additional assessments required to ensure safet y of subjects should be 
administered as deemed necessary  on a case by case basis. Under no circumstances is an 
Commercially Confidential Information
Novartis Confidential Page 82
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
investigator allowed to collect additiona l data or conduct any additional procedures for any 
research related purpose involving an y investigational drugs under the protocol.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC and health authorities, where required, it cannot be 
implemented.
13.1 Protocol A mend ments
Any change to the protocol can only be made in a written protocol amendment that must be 
approved by Novartis, Health Authorities where required, and the IRB/IEC prior to 
implementation.
Amendments that are intended to eliminate an apparent immediat e hazard to subjects may be 
implemented immediately , provided the Health Authorities are subsequently  notified by 
protocol amendment and the reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section 9 (Safet y Monitoring) must be followed and the Study  Lead 
informed.
Novartis Confidential Page 83
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
14 References
Ataga KI, Kutlar A, Kanter J, et al (2017) Crizanlizumab for the prevention of pain crises in 
sickle cell disease. N Engl J Med; 376:429 -39.
Akohoue SA, Shankar S, Milne GL, et al (2007) Energy  expenditure, inflammation, and 
oxidative stress in steady -state adolescents with sickle cell anemia. Pediatr. Res. p. 233-8.
Andersen PK, Gill RD (198 2) Cox’s regression model for counting processes: A large sample 
study . Ann Stat.; 10: 1100-20. 
Booth C, Inusa B, Obaro SK (2010) Infection in sickle cell disease: a review. Int J Infect Dis. 
2010; 14: e2-e12.
Cain DM, Vang D, Simone DA, et 
al (2012) Mouse models for study ing pain in sickle 
disease: effects of strain, age and acuteness. Br J Haematol; 156:535 -44.
Chen F (2011) The RANDOM statement and more: moving on with PROC MCMC. 
SAS Global Forum Proceedings, p. 334-2011.
Church LD, Cook GP, McDermott MF (2008) Primer: inflammasomes and interleukin 1beta 
in inflammatory  disorders. Nat Clin Pract Rheumatol p. 34-42.
Dampier C, Ely B, Brodecki D,et al (2002 a) Characteristics of pain management at home in 
children and adolescents with sickle cell disease by  using diary  self-reports. J Pain; 3(6):461 -470.
Dampier C, Ely  E, Brodecki D, et al (2002 b) Home management of pain in sickle cell disease: 
a daily  diary  study  in children and adolescents. J. Pediatr. Hematol. Oncol. p. 643 -
7.
Dampier C, Ely E, Eggleston B, et al (2004) Physical and cognitive -behavioral activities used 
in the home management ofsickle pain: a daily  diary study in children and adolescents. 
Pediatr Blood Cancer p. 674-8.
Dampier C, Lieff S, LeBeau P, et 
al (2010) Health- related quality  of life in children with 
sickle cell disease: a report from the Comprehensive Sickle Cell Center s Clinical Trial 
Consortium. Pediatr Blood Cancer p. 485 -94.
Dinarello (1999) IL-18: A Th1-inducing, proinflammatory  cytokine and new member of the 
IL-1 famil y.  J Allergy  Clin I mmunol. 103:11
-24.
Dutra FF, Alves LLS, Rodrigues D, et al (2014) Hemol ysis-induced lethality  involves 
inflammsome activation by  heme. PNAS; 111:E4110 -8.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 84
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
Fisch R, Jones I, Jones J, et al (2015) Bayesian Design of Proof-of-Concept Trials. 
Therapeutic Innovation & Regulatory  Science; 49:155 -162.
Ford ES, Giles WH, Myers GL, et al (2003) C-reactive protein concentration distribution 
among US children and young adults: findings from the National Health and Nutrition 
Examination Survey , 1999 -2000. Clin. Chem. p. 1353-7.
Heeney  MM, Hoppe CC, Abboud MR, et al (2016 ) A multinational trial of Prasugrel for 
sickle cell vaso -occlusive events. New Engl J Med ; 374:625 -35.
Jacob E, Duran J, Stinson J, et al (2013) Remote monitoring of pain and symptoms using 
wireless technology  in children and aadolescents with sickle cell disease. J Am Assoc Nurse 
Pract; 25:42-54.
Kanavaki I, Makry thanasis P, Lazaropoulou C, et al (2012) Adhesion molecules and high-
sensitivity  C-reactive protein levels in patients with sickle cell beta- thalassasemia. Eur J Clin 
Invest; 42:27-33.
Kauf TL, Coates TD, Huazhi L, et 
al (2009) The cost of health care for children and adults 
with sickle cell disease. Am J Hematol; 84:323-7.
Kaul TL & Gram H (2011) Anti- IL-β antibody -based therapy  to ameliorate inflammation and 
vaso-occlusion in sickle cell disease. ASH Annual Meeting Abstracts;118:848.
Kerman J (2011) Neutral noninformative and informative conjugate beta and gamma prior 
distributions. Electron. J. Statist. 5: 1450-70.
Kieser M and Friede T (2003). Simple procedures for blinded sample size adjustment that do 
not affect the ty pe I error rate. Statist. Med.; 22:3571 -81.
Krishnan S, Sett y Y, Betal SG, et al (2010) Increased levels of the inflammatory  biomarker C -
reactive protein at baseline are associated with childhood sickle cell vasocclusive crises. Br. J. 
Haematol. p. 797 -804.
Lagunju I, Sodeinde O, Brown B, et al (2014) Transcranial Doppler ultrasonograph y in 
children with sickle cell anemia: Clinical and laboratory  correlates for elevated blood flow 
velocities. J Cl in Ultrasound p. 89 -95.
Maikler VE, Broome ME, Bailey  P, et al (2001) Childrens’ and Adolescents’ use of diaries 
for sickle cell pain. J Soc Ped Nurses:6:161 -69.
McGrath PJ, Walco GA, Turk DC, et al (2008) Core outcomes domains and measures for 
pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J 
Pain; 9:771-783.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 85
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
Mohammed FA, Mahdi N, Sater MA, et al (2010 )The relation of C -reactive protein to vaso -
occlusive crisis in children with sickle cell disease. Blood Cells, Molec Dis; 45:293 -96.
Morel JC, Parkc CC, Woods JM, et al (2001) A Novel Role for Interleukin -18 in Adhesion 
Molecule Induction through NFkB andPhosphatidy linositol (PI) 3-Kinase - dependent Signal 
Transduction Pathway s  J Biol Chem; 276:37069 –75.
Nouraie M, Lee JS, Zhang Y, et al (2013) The relationship between the severity  of hemoly sis, 
clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and 
Europe. Haematologica .
p. 464-72.
Qari MH, Dier U, Mousa SA (2012) Biomarkers of inflammation, growth factor and 
coagulation activation in patients with sickle cell disease. Clin Applied Thromb/Hemostas; 
18:195 -
200.
Pagé MG, Katz J, Stinson J, et al (2012) Validation of the numerical rating scale for pain 
intensity  and unpleasantness in pediatric acute postoperative pain: sensitivity  to change over 
time. J Pain p. 359-69.
Panepint o JA, Torres S, Bendo CB, et al (2014) Ped sQLtm Multidimensional Fatigue Scale in 
sickle cell disease: feasibility , reliability  and validity . Pediatr Blood Cancer; 61:171 -7.
Pashankar FD, Manwani D, Lee MT, et al(2015) Hydroxyurea Improves Oxygen Saturation 
in Children With Sickle Cell Disease. J . Pediatr. Hematol. Oncol. p. 242 -3.
Porter LS, Gil KM, Sedway  JA, et al (1998) Pain and stress in sickle cell disease: an analysis 
of daily  pain records. Int J Behav Med p. 185 -203.
Rigante D, Frediani B, Cantarini L (2016) A comprehensive overview of the hereditary  
periodic fever s yndromes. Clin Rev Alleg Immunol; https://doi.or g/10.1007/s12016 -016-
8537-8.
Ruskin D, Lalloo C, Amaria K, et 
al (2014) Assessing pain intensity  in children with chronic 
pain: convergent and discriminant validity  of the 0 to 10 numerical rating scale in clinical 
practice. Pain Res Manag p. 141-8.
Saraf SL, Molokie RE, Nouraie M, et 
al (2014) Differences in the clinical and genot ypic 
presentati on of sickle cell disease around the world. Paediatr Respir Rev p. 4-12.
Setty  BN, Stuart MJ, Dampier C, et al (2003) Hypoxaemia in sickle cell disease: biomarker 
modulation and relevance to pathophy siology . Lancet p. 1450 -5.
Shapir o BS, Dinges DF, Orne EC, et al(1995) Home management of sickle cell-related pain 
in children and adolescents: Natural history  and impact on school attendance. Pain; 61:139 -
144.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 86
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
Van Beers EJ, Yang Y, Raghavochari N, et al (2015) Iron, inflammation, and early death in 
adults with sickle cell disease. Circ Res; 116:298 -306.
Van Hooff ML,Geurts SA, Kompier MA, et al (2007) "How fatigued do you currently  feel?" 
Convergent and discriminant validity  of a single -item fatigue measure. J Occup Health p. 224 -34.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 87
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
15 Appendix 1: Liver Event Definitions and Foll ow-up 
Requirements
Table 15-1 Liver Event Definitions
Definition Thresholds
Potential Hy’s law cases ALT > 3 × ULN and TBL > 2 × ULN without initial 
increase in ALP to > 2 × ULN
ALT elevation with coagulopathy ALT > 3 × ULN and INR > 1.5 (in the absence of 
anticoagulation)
ALT elevation accompanied by sy mptoms ALT > 3 × ULN accompanied by (general) malaise, 
fatigue, abdominal pain, nausea, or vomiting, or rash, 
or eosinoph ilia
Isolated ALT elevation ALT > 8 × ULN
5 x ULN < ALT ≤8 x ULN
3 x ULN < ALT ≤5 x ULN
Isolated ALP elevation ALP > 2 × ULN (in the absence of known bone 
pathology)
OthersAny clinical event of jaundice (or equivalent term)
Any adverse event potentially indicative of liver 
toxicity
Table 15-2 Actions required for Liver Events
Criteria Actions required
Potential Hy’s Law case
Discontinue the study treatment immediately
Hospitalize, if clinically appropriate
Establish causality
Complete CRFs per liver event guidanceALT elevation with coagulopathy
ALT elevation accompanied by 
symptoms
Isolated ALT elevation > 8 × ULN
Jaundice
Isolate d ALT elevation > 5 to ≤ 8× 
ULNIf confirmed, consider interruption or discontinuation of 
study drug
If elevation persists for more than 2 weeks, discontinue 
the study drug
Establish causality
Complete CRFs per liver event guidance
Isolate d ALT elevation > 3 to ≤ 5× 
ULN (patient is asy mptomatic)Monitor liver chemistry tests two or three times weekly
Isolated ALP elevation Repeat liver chemistry  tests within 48 -72 hours
If elevation is confirmed, measure fractionated ALP; if 
>50% is of liver origin, establish hepatic causality
Complete CRFs per liver event guidance
Novartis Confidential Page 88
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
Criteria Actions required
Any AE potentially indicative of liver 
toxicityConsider study treatment interruption or discontinuation
Hospitalize if clinically appropriate
Complete CRFs per liver event guidance
Table 15-3 Exclusion of underly ing liver disease
Disease Assessment
Hepatitis A, B, C, E IgM anti -HAV; HBSAg, IgM anti -HBc, HBV DNA; anti -HCV, 
HCV RNA, IgM & IgG anti -HEV, HEV RNA
CMV, HSV, EBV infection IgM & IgG anti -CMV, IgM & IgG anti -HSV; IgM & IgG anti -
EBV
Autoimmune hepatitis ANA & ASMA titers, total IgM, IgG, IgE, IgA
Alcoholic hepatitis Ethanol history, γ-GT, MCV, CD -transferrin
Nonalcoholic steatohepatitis Ultrasound o r MRI
Hypoxic/ischemic hepatopathy Medical histor y: acute or chronic CHF, hypotension, hypoxia, 
hepatic venous occlusion. Ultrasound or MRI.
Biliar y tract disease Ultrasound or MRI, ERCP as appropriate.
Wilson disease Caeruloplasmin
Hemochromatosis Ferritin, transferrin
Alpha -1-antitr ypsin deficiency Alpha -1-antitr ypsin
Novartis Confidential Page 89
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
16 Appendix 2: Specific Renal A lert Criteria and A ctions
Table 16-1 Specific Renal A lert Criteria and Actions
Criteria Action required
Serum creatinine (sCr) increase
25 –49% compared to baselineConsider causes and possible interventions
Follow up within 2 -5 day s
Serum creatinine increase >50% Consider causes and possible interventions
Repeat assessment within 24 -48h if possible
Consider drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected
Consider hospitalization and specialized 
treatment
Protein -creatinine or albumin -creatinine ratio 
increase ≥ 2 -fold
or
new o nset dipstick proteinuria ≥ 1+
or
Albumin -creati nine ratio (ACR) ≥ 30 mg/g or 
≥3 mg/mmol;
or
Protein -creatinine ratio (PCR ) ≥ 150 mg/g or 
>15 mg/mmolConsider causes and possible interventions
Assess serum albumin & serum protein
Repeat assessment to conf irm
Consider drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected
New onset glucosuria on urine dipstick (unless 
related to concomitant treatment, diabetes)Assess & document:
Blood glucose (fasting)
Serum creatinine
Urine albumin -creatinine ratio
New hematuria on dipstickAssess & document :
Urine sediment microscopy
Assess sCr and urine albumin- creatinine ratio
Exclude infection, trauma, bleeding from the 
distal urinary tract/bladder, menstruation
Consider bleeding disorde r
Additional specialized assessments are available to assess renal function or renal pathology . 
(Note: In exceptional cases when a nephrologist considers a renal biopsy , it is strongl y 
recommended to make specimen slides available for evaluation by Novartis to potentiall y 
identify  project -wide patterns of nephrotoxicity .)
Novartis Confidential Page 90
Amended Protocol Version v05 (Clean ) Protocol No. CACZ885X2206
Whenever a renal event is identified, a detailed subject history  and examination are indicated 
to identify , document and potentiall y eliminate risk factors that may have initiated or 
contributed to the event:
Blood pressure assessment (after 5 min rest, with an appropriate cuff size)
Signs and s ymptoms such as fever, headache, shortness of breath, back or abdominal pain, 
dysuria, hematuria, dependent or periorbital edema
Changes in b lood pressure, body  weight, fluid intake, voiding pattern, or urine output
Concomitant events or procedures such as trauma, surgical procedures, cardiac or hepatic 
failure, contrast media or other known nephrotoxin administration, or other potential 
causes of renal d ysfunction, e.g., dehy dration, hemorrhage, tumor l ysis
Table 16
-2 Follo w-up of renal events
Action Follow up
Assess *, document and record in the Case 
Report Form (CRF) or via electronic data load. 
Review and record possible contributing 
factors to the renal event (co -medications, 
other co -morbid conditions) and additional 
diagnostic procedures (MRI etc) in the CRF.Urine dipstick and sediment microscopy
Blood pr essure and body weight
Serum creatinine, electrolytes (sodium, 
potassium, phosphate, calcium), bicarbonate and 
uric acid
Urine output
Monitor subject regularly (frequency at 
investigator’s discretion) until:Event resolution: (sCr within 10% of baseline or 
protein -creatinine ratio within 50% of baseline)
or
Event stabilization: sCr level with ±10% 
variability over last 6 months or protein -creatinine 
ratio stabilization at a new level with ±50% 
variability over last 6 months.
* Urine osmolality : in the absence of diuretics or chronic kidney  disease this can be a very 
sensitive metric for integrated kidney  function that require s excellent tubular function. Ahigh 
urinary  osmolality  in the setting of an increase in sCr will point toward a “pre-renal” cause 
rather than tubular toxicity.